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ABSTRACT 
Proper vision relies heavily on the eye’s ability to maintain optical clarity and structural 
integrity under daily fluctuations in pressure, variations in humidity and temperature, 
constant muscular strain and sudden movements.  Therefore, as is the case for many 
organs, proper function depends on the physical properties of eye tissues.  Many diseases 
are associated with altered chemical and mechanical states of tissue and a resulting loss of 
functionality.  Diseases that cause changes in visual acuity, such as degenerative myopia 
and keratoconus, may be treatable by engineering the mechanical properties of the sclera 
and cornea. 
Degenerative myopia is the leading cause of untreatable blindness in China, Taiwan, and 
Japan, and is ranked 7th in the United States.  The disease entails progressive stretching and 
thinning of the scleral tissues that leads to elongation of the eye and posterior staphyloma 
formation.  While refractive errors are readily corrected for patients, there is an increased 
likelihood of visual loss due to stretching of the chorioretinal tissues.  Retinal tears and 
detachments as well as choroidal neovascularization create debilitating problems.  
Currently, there is no treatment to retard or prevent the axial elongation of the globe in 
degenerative myopia. 
Keratoconus affects nearly 1 in 2000 Americans and is identified by the conical shape that 
the cornea forms.  The thinning and weakening of the cornea in this disease causes the 
cornea to bulge out under normal intraocular pressures.  With increasing degrees of 
protrusion, correction by spectacles and contact lens wear becomes more and more 
difficult.  Eventually 20% of patients will require corneal transplantation because refractive 
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correction is no longer possible.  Further, patients with thin corneas are at high risk for 
complications after LASIK and similar refractive surgeries.  Early clinical data supports the 
efficacy of ultraviolet light activation of topically applied riboflavin to increase the corneal 
modulus and prevent progression of the disease. 
The use of riboflavin activated by ultraviolet light and the use of crosslinkers to treat tissue 
works on the presupposition that by increasing the strength and mechanical stability of the 
tissue, the disease progression may be halted.  Our studies in vitro indicate that crosslinking 
can improve tissue mechanical stability and resistance to deformation. 
Mechanical characterization of tissue has relied heavily on the use of the intact globe 
expansion method which we have developed.  While other measurement techniques 
(uniaxial tensile tests, shear rheology) are used in the field of eye biomechanics, our 
evaluation of the testing methods and variability of the results indicates that considerable 
effort is required to achieve reliable results.  The intact globe expansion test provides 
reliable measurements, with relatively few samples, and mimics the type and distribution of 
stresses inherent in the natural boundary conditions of the eye.  Furthermore, application of 
high intraocular pressures provides a way to study shape changes of the sclera and cornea 
which are similar to those exhibited in myopia and keratoconus.  Potential treatments that 
show an ability to prevent ocular distension in this method have a chance of preventing the 
deformations that occur in vivo in the diseases.  Therefore, this method has been used to 
evaluate treatments developed in the course of this thesis. 
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Our treatment development has gained direction from the previous example of 
Wollensak and Speorl who pioneered the use of riboflavin and ultraviolet-light-induced 
crosslinking of tissue.  Light activated crosslinking provides spatial and temporal control of 
treatments.  The choice of different photoinitiator systems, such as Eosin Y (EY) and 
triethanolamine (TEOA) allows the use of visible light (525 ± 16 nm), and at the irradiation 
doses necessary to achieve stabilization of the eye mechanical properties in vitro (6–8 
mW/cm2), calculations indicate that treatments will be more than a factor of 6 under the 
thresholds set by ANSI guidelines. 
Eye stabilization in vitro has been demonstrated through treatment of either the sclera or 
the cornea with the use of EY and TEOA.  For myopia treatment, drug delivery in vitro 
used low concentrations (0.0289 mM EY, 90 mM TEOA) , while the switch to in vivo drug 
delivery by subconjunctival injection required the use of higher concentrations (0.298 mM 
EY, 90 mM TEOA) to achieve the same stabilization during in vitro expansion.  
Keratoconus treatments comparing the protocols for riboflavin that are used in the clinic to 
treatment with EY/TEOA demonstrate similar capabilities of eye stabilization.  Further, 
penetration studies of EY/TEOA show the possibility of delivering drug to the stroma 
without removal of the epithelium.  In combination with the reduced treatment time of the 
visible light treatment (10 minutes as opposed to 35 for the riboflavin/UV treatment), this 
could vastly improve the current treatment techniques. 
Biocompatibility studies of the treatments indicate excellent tolerance to the light and drug 
in both rabbits and guinea pigs.  Although we discovered that treatment with 0.09 mM 
EY/90 mM TEOA was not able to prevent development of form deprivation myopia in a 
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guinea pig model, there were no ill effects of the treatment seen during the life of the 
animals.  Tests on normal growth of guinea pig eyes indicate that treatment with a higher 
dose (0.289 mM EY/90 mM EY) causes substantial changes to eye shape without toxicity.  
These changes are manifested in shifts in the refractive error and ocular length that persist 
for the duration over which the animals are monitored. 
In summary, the mechanical measurement technique developed in this work has usefulness 
as a tool to characterize tissue strength and as a tool for screening and comparing treatment 
efficacy.  The visible light system designed for the purposes of treating degenerative 
myopia and keratoconus shows an ability to stabilize eye shape in vitro, demonstrates 
biocompatibility, and does so with light doses that are deemed safe levels for clinical 
applications. 
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"There is no better way to thank God for your sight than by giving a helping hand to 
someone in the dark."—Helen Keller 
 
1.1 Importance of Vision 
Our culture recognizes the importance of vision, and it is an integral part of our lives and 
language.  Vision allows processing of large amounts of information in a short period of 
time:  “A picture is worth a thousand words.”  We associate the loss of sight with an 
inability to cope in the world:  “Like the blind leading the blind.”  Our reluctance to lose 
the ability to see has driven the creation of a world of research, medicine, and business 
focused on restoring sight.  Americans spend approximately $15 billion a year on eyewear,1 
and the National Eye Institute estimates that the economic cost associated with visual 
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disabilities in 2003 was nearly $63 billion.3  Our research, like many other peoples’ 
research, delves into the treatment of eye diseases in order to prevent eventual blindness. 
To understand the nature of the two diseases we study (keratoconus and degenerative 
myopia), it is important to understand the role that individual ocular components play in 
allowing the eye to see.  The eye is an amazing organ whose function is to collect light and 
transform it into signals interpretable by the brain.  The cornea is the clear front of the eye 
and serves as window through which light enters the eye (Figure 1.1).  The curvature of the 
cornea and its refractive index difference from air are responsible for nearly 2/3 of the eye’s 
focusing power.  Light that enters through the cornea then intercepts the iris.  The iris acts 
as an aperture and controls the amount of light entering through the pupil.  Its constriction 
restricts the amount of light in bright conditions, and its ability to dilate allows more light 
to enter in dark conditions.  Immediately behind the pupil is a flexible crystalline lens.  The 
ciliary muscle can change the shape of this lens, allowing adjustable focus of the world.  
Images are focused through the vitreous onto the retina.  The vitreous is a collagen based 
gel that is nearly 99% water.  This gel is thought to provide structural support, preventing 
damage to the eye’s components during sudden movements or collisions.  The retina is 
responsible for transforming light into chemical signals.  Photoreceptors in the retina 
absorb light and transmit signals along nerves that exit the eye through the optic nerve, 
which connects to the brain.  Around the whole eye, and connected to the cornea, is a tissue 
called the sclera, which is responsible for maintaining the proper shape of the eye. 
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1.2 Diseases of the Eye—Myopia and Keratoconus 
If any one of the ocular components does not function properly, vision is impaired and in 
some cases, uncorrectable.  The shape of the eye defined by the cornea and sclera plays a 
great role in the ability to see clearly.  In the proper shape, incoming light is bent by the 
cornea and images are focused onto the plane of the retina.  This state of vision is 
emmetropia (Figure 1.2a).  If the corneal curvature changes to become flatter, it loses some 
of its power and images are focused behind the retina (Figure 1.2b).  Steepening of corneal 
curvature increases its power and images are focused in front of the retina (Figure 1.2c).  In 
these two cases, the eye becomes hyperopic or myopic, respectively.  Likewise, changes in 
the shape of the sclera move the image focal plane off the retina.  Shorter, hyperopic eyes 
Figure 1.1.  This illustration of the eye 
anatomy indicates the location of the 
cornea, sclera, and conjunctiva.  
Reproduced from the National Eye 
Institute, National Institutes of Health
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have light focused behind the retina, while longer myopic eyes have light focused in 
front of the retina.  Without correction from spectacles, contacts, or surgery, vision is 
impaired resulting in farsightedness (hyperopia) or nearsightedness (myopia) (Figure 2.1.g, 
h). 
 
Figure 1.2.  A) In the emmetropic state, images are focused onto the plane of the retina.  
In hyperopia, images are focused behind the plane of the retina, and in myopia they are 
focused in front of the retina.  B) A flatter cornea focuses images behind the retina, while 
C) a steeper cornea focuses light in front of the retina.  D) A shorter eye moves the retina 
in front of the focal plane and E) a longer eye moves the retina behind the focal plane.  
Images from the National Eye Institute, National Institutes of Health depict eyesight with 
F) emmetropia, G) hyperopia, and H) myopia. 
  
F) G) H)
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Diseases that create shape changes in either the sclera or the cornea are bound to effect 
vision.  Two diseases that we have studied in particular are degenerative myopia, which 
creates an elongated eye through the thinning and stretching of the sclera, and keratoconus, 
which creates a cone shaped cornea that bulges outward. 
1.2.1 Degenerative myopia 
Myopia affects 30% of the population in the U.S. and Europe, and 70–90% of the 
population in some Asian countries.4-6  High myopia of greater than 8 diopters affects 0.2–
0.4% of the US population and up to 1% of the population in Asian countries.7-13  
Degenerative myopia is classically defined as the form of myopia characterized by 
progressive stretching and thinning of scleral tissues leading to globe elongation and to 
posterior staphyloma formation (Figure 1.3a).12  As scleral tissues stretch and thin, there is 
associated stretching of retinal and choroidal tissues that promotes visual loss.  While 
visual loss from macular atrophy and choroidal neovascularization are most common in 
degenerative myopia, patients with this disease are also more prone to retinal detachment 
and macular hole formation.  Although a large population is affected by this disease 
worldwide, there is currently no effective method to arrest progression and reduce the rate 
of visual loss. 
The excessive axial enlargement of the globe that occurs in degenerative myopia occurs 
preferentially in the posterior pole.  The causes of scleral thinning and stretching that occur 
during this elongation are incompletely understood, but reduction of collagen fibril 
diameter, enhanced turnover of scleral collagen, and alteration of scleral 
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glycosaminoglycans are contributory factors.14  As the mechanical properties of the 
sclera are altered in myopia, it is hypothesized that the eye is prone to stretching due to the 
load effect of intraocular pressure. 
 
1.2.2 Keratoconus 
Keratoconus is the most common corneal dystrophy, affecting approximately 1/2000 
individuals with no gender or racial preference.  The disease is nearly always bilateral and 
causes progressive paracentral corneal thinning.15, 16  Patients usually present in their teens 
with increasing myopia and irregular astigmatism due to conical corneal steepening (Figure 
1.3b).  As the disease progresses, spectacles cannot correct the irregular astigmatism, and 
patients need to wear contact lenses to optimize their visual acuity.  In approximately 20% 
of patients, penetrating keratoplasty (corneal transplantation) is required because of contact 
lens intolerance and/or loss in best corrected visual acuity.  Keratoconus is one of the 
leading causes of penetrating keratoplasty in the US. 
Figure 1.3.  A) Thinning and stretching in the posterior pole 
characteristic of degenerative myopia.  B) Conical shape of the 
cornea resulting from a thinning in keratoconus and photograph 
showing a keratoconus eye.  Courtesy of Indiana University School 
of Medicine, Department of Ophthalmology 
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Clinical diagnosis of keratoconus is generally straightforward.  In addition to 
progressive myopia and astigmatism, various changes are evident at the slit lamp including 
apical corneal thinning, iron line formation (Fleischer ring) at the base of the “cone”, 
stromal scarring, and in some cases, corneal hydrops due to rupture of Descemet’s 
membrane.  Corneal topographical analysis has made it easier to quantify progression of 
keratoconus as well as to detect subclinical disease (forme fruste keratoconus).17-19  The 
latter has come into increasing focus because patients with forme fruste keratoconus who 
undergo corneal refractive procedures, such as LASIK, can develop post-LASIK ectasia 
requiring corneal transplantation.20-23  Given the growing frequency of corneal refractive 
surgery, forme fruste keratoconus is increasingly recognized as an important 
contraindication to excimer laser ablative procedures. 
The genetic and molecular abnormalities underlying keratoconus are unknown.  Increased 
extracellular matrix degradative enzyme activity has been reported,24, 25 as has a mutation 
in superoxide dismutase (SOD1) that might increase oxidative damage to the cornea.26 
1.2.3 Corneal and Scleral Structure 
In keratoconus and myopia, changes to the extracellular matrix and thinning of the tissue 
result in a reduction of tissue strength and misshapen eyes.  The corneal and scleral 
extracellular matrices are composed of very similar components.  Both tissues are 75–78% 
water and the remaining mass consists mostly of collagen and glycosaminoglycans 
(GAGs).27, 28  The majority of the dry mass is type I collagen.  Collagen is a triple helix 
molecule with glycine located at every third position along the protein.  Collagen self 
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assembles to form fibers of stacked molecules linked end to end, and these fibers 
aggregate to form fibrils which can be arranged in lamellae.  In addition to collagen, the 
cornea and sclera also have GAGs, which are highly charged molecules formed of 
dissacharide subunits.  These GAGs can also connect to protein cores forming very large, 
highly charged species—proteoglycans.  These highly charged species attract water to the 
tissue.  The collagen and proteoglycans interact to form the extracellular matrix. 
While the basic components are similar, differences in fibril arrangement give the cornea 
and sclera distinct properties.  The collagen fibers in the cornea have regular spacing 
between them, and have a very narrow distribution of fiber diameters.  The fibrils are 
organized into layers with fibrils running parallel within the layer.  Stacks of layers are 
arranged with sequential layers having orthogonal fibers.  Such carefully controlled 
arrangement of the fibers creates the optically clear cornea.  In the sclera, the fibers have a 
large distribution of diameters, have irregular spacing, and although organizing into ribbons 
of fibers, these ribbons interweave instead of stacking like in the cornea.  All these 
differences contribute to the scattering properties of the sclera that make it white instead of 
clear. 
Despite the differences in structure, the cornea and sclera are made of essentially the same 
components, and a treatment for one tissue could possibly work for the other.  Based on the 
weakening of tissue in degenerative myopia and keratoconus, a way to alter the tissue and 
restore mechanical stability could be a suitable treatment. 
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1.3 Importance of Mechanical Properties—Diseases and Measurements 
As discussed in the previous section, changes to the cornea and sclera during keratoconus 
and degenerative myopia result in changes of the mechanical properties of these tissues.  
With the disease, they are more susceptible to stresses, and undergo deformations that 
affect vision.  The association of tissue mechanical state with proper function is seen in 
other areas of the eye and other parts of the body as well.  A stiff lens prevents adjustable 
focus; a weakened lamina cribrosa contributes to pinching of the optic nerve in glaucoma.  
In other parts of the body, stiffening of collagen and elastin in the skin causes wrinkles, 
weakening of blood vessel walls can result in aneurysms, weakness of containing 
membranes can result in hernia, and weakened bones in osteoporosis can increase risk of 
bone fracture.  While the healthy tissue has a mechanical state that allows proper function, 
diseased tissue with an altered mechanical state is susceptible to failure.  Treatments can be 
developed with the goal of restoring proper mechanical state or replacing tissue with 
something that matches the natural tissue mechanics. 
In order to characterize the healthy, diseased, and treated tissue, it is necessary to quantify 
the mechanical properties in each state.  Ideally, tests on mechanical properties would be 
done in vivo without altering the tissue.  Unfortunately this is often difficult and testing 
methods must be designed to mimic the types of stresses and strains experienced in vivo.  
Furthermore, it may be necessary to exaggerate the stresses and strains in order to obtain 
results that show a quantifiable difference between tissues within time limits imposed on 
laboratory work.  Reliable methods would maintain a tissue’s original condition as much as 
possible and provide repeatable results.  In Chapter 2, we compare tensile, shear, and 
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expansion tests in order to evaluate variability of the methods and determine their 
usefulness for characterizing cornea and sclera.  In addition, intact globe expansion tests 
provide a method of evaluating the treatments developed for keratoconus and myopia. 
1.4 Potential Treatments 
In our understanding of the disease state of keratoconus and degenerative myopia, we see 
that a loss of the mechanical stability of the tissue leads to deformations that cause visual 
problems.  If however, there were methods of preventing the deformations, reinforcing the 
tissue, and restoring mechanical stability, then there would be the possibility of treating 
these diseases.  Increasing the strength, or modulus, of the cornea and sclera might prevent 
ocular distension and reduce progression of keratoconus and degenerative myopia. 
This section discusses the use of crosslinkers as viable treatment options and, in particular, 
discusses the merits of photoactivated systems.  Such systems increase the ability to tailor 
treatments to individual patients by providing spatial localization and temporal control of 
crosslinking. 
1.4.1 Crosslinking 
Crosslinking in tissues occurs naturally with aging and is normally associated with 
undesirable changes.2, 29-38  It causes stiffening of the skin, cartilage, heart, cornea, lens, 
lung, arteries, and nearly every tissue with an abundance of extracellular matrix.  This 
stiffening is associated with wrinkling, osteoarthritis, cardiovascular disease, and vision 
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problems.  Many of the crosslinks are advanced glycation end-products (AGEs) that 
result from the reaction of sugars with amine groups in proteins (Figure 3.1).39-44 
An increased amount of AGEs is common in diabetics as a result of the inability to 
properly control sugar levels in the body.  This predisposes diabetics to many problems, but 
interestingly, there is evidence that crosslinking of corneal collagen that occurs in diabetes 
provides protection against keratoconus.45  Further, studies using common collagen 
crosslinkers such as glyceraldehyde, methylglyoxal, and glutaraldehyde within the cornea 
and sclera indicate that strength of the tissue is increased after crosslinking.46-50  Our 
experiments with glyceraldehyde crosslinking show a greater than 300% increase in shear 
modulus after crosslinking of sclera (Figure 2.16), and demonstrate the ability of 
crosslinked eyes (cornea and sclera) to resist expansion at elevated intraocular pressures 
(Figure 2.26). 
The ability to use crosslinking agents to strengthen ocular tissues and prevent expansion is 
not attractive clinically.  The extent of crosslinking produced by a given dose of crosslinker 
using the “Maillard reaction” (Figure 1.4) may prove difficult to control and monitor.  The 
initial reaction is reversible and does not necessarily lead to the formation of crosslinks:  
the Schiff base undergoes modification, typically forming more stable Amadori products, 
which tend to accumulate over time and through further modification may form crosslinks 
or stable pendant adducts.  The transition from Amadori product to AGE can take from 
minutes to days, so that even after removal of excess sugars, continued crosslinking of 
tissue occurs.  This effect is evident in the additional 50% increase of the shear modulus 
observed over the first 24 hours after rinsing excess glyceraldehyde from the sclera (Figure 
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2.16).  A further aspect of the lack of control over the crosslinking reaction is the fact 
that there is no way to turn on and off the reactivity of the reducing sugars.  Protein 
modification is more likely in areas of high crosslinker concentration, and these small 
molecules spread quickly by diffusion—both into the intended tissue and surrounding 
tissues.  This poses a danger in the eye where crosslinking in sensitive areas, such as the 
retina, should be avoided. 
    
 
Figure 1.4.  Reproduced from Zieman & Kass2
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1.4.2 Photoactivated Crosslinking 
Photoactivated crosslinking provides a high degree of control that enables precise 
treatments to avoid damaging sensitive areas of the eye, or even surrounding tissues.  
Light-activated compounds could be delivered in the dark and allowed to diffuse to the 
correct locations in tissue.  Those locations could be selectively exposed to irradiation, 
inducing crosslinking locally while adjacent tissue is unexposed and safe from 
crosslinking.  Further, the use of light activation could provide the ability to start 
crosslinking with light exposure, and after achieving the desired level of crosslinks, stop 
further reactions by turning off the light.  Treatment location and strength could be 
customized specifically for individual patients. 
1.5 Outline of Thesis 
The measurement techniques typically used for mechanical characterization of the cornea 
and sclera have individual advantages and disadvantages that we evaluate in Chapter 2.  
Our work has led to an improved intact globe expansion method that uses relatively simple 
loading procedures, has low variability, and provides the ability to discriminate between 
treatments that are developed specifically for keratoconus and degenerative myopia. 
Chapters 3 and 4 discuss the treatment development process.  Chapter 3 discusses 
advantages of photoactivated systems including temporal and spatial control of the 
reaction.  The search for a biocompatible system that uses safe levels of light led to the 
choice of a visible light-activated system using Eosin Y and triethanolamine.  Chapter 4 
presents the use of interpenetrating polymer networks to enhance mechanical properties of 
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the tissue.  Surprisingly, results show that polymer interpenetrating networks are not 
necessary because crosslinking with initiator alone achieves comparable degrees of tissue 
stabilization. 
Chapters 5 and 6 illustrate the strengthening of sclera and cornea for the treatment of 
myopia and keratoconus respectively.  In Chapter 5, intact globe expansion tests are used to 
determine the potential for treatments to stabilize eye shape in vivo and animal testing 
provides biocompatibility as well as in vivo treatment responses.  In Chapter 6, penetration 
studies are used to demonstrate that treatment without removal of the epithelium may be 
possible, and intact globe expansion tests show the visible-light-activated treatment 
produces equivalent stabilization of the cornea compared to methods that are currently in 
clinical trials. 
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This work includes contributions from Joyce Huynh, Muzhou Wang, and Meredith 
Wiseman.  Undergraduates Muzhou Wang and Meredith Wiseman contributed to the 
method development necessary for tensile tests and intact globe expansion, respectively.  
Graduate student Joyce Huynh assisted with intact globe expansion experiments during her 
first year. 
2.1 Introduction to the Field of Biomechanics 
The field of biomechanics has arisen from a desire to understand how living things work.  
One of the earliest texts relating to biomechanics came from Aristotle’s writing “On the 
Parts of Animals” (394–322 B.C.).  Other contributors to the field include Galileo Galilei, 
Robert Hooke, Isaac Newton, and Thomas Young.  Contributions from them and many 
others help us understand things ranging from blood flow and respiration to locomotion and 
talking. 
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Findings related to the human body have greatly advanced medicine.  Respirators assist 
with breathing, artificial heart valves replace faulty ones, and bones and joints are replaced 
with prosthetic devices.  Advances within medicine have relied on methodology of 
engineering and biomechanics to understand problems associated with diseased, injured, or 
broken systems in relation to healthy working systems.  Characterization of bones has lead 
to earlier detection of osteoporosis, better joint materials, and even injectable materials to 
fill the holes and gaps in damaged bones. 
In relation to the eye, there are obvious mechanical changes of the sclera and cornea 
associated with degenerative myopia and keratoconus (Chapters 1, 5, & 6).  
Characterization of these changes could be useful for understanding and diagnosing the 
diseases.  Understanding the changes that occur could also lead to new insights for treating 
or preventing the diseases.  In addition, clinical treatments aimed at modifying the 
mechanical properties of the cornea and sclera can be evaluated using methods of 
biomechanics. 
In this chapter we present methods used for the characterization of the cornea and sclera, 
and we evaluate the reliability of the methods based on the variability of results and the 
relationship to in vivo conditions.  Our findings indicate that results are often method-
dependent, and for studies related to keratoconus and degenerative myopia, there are 
advantages in using an intact globe method that maintains an almost natural configuration 
of the tissue. 
 
 II-3
2.2 Principles Behind Measurements 
In order to understand the tissue, we are interested in studying the forces imposed on and 
the mechanical responses of the system.  Although biomaterials are typically complex 
inhomogeneous materials, our understanding of them has been built up from very basic 
understandings of ideal solids and liquids. 
 
Ideal or Hookian solids can be thought of as isotropic homogeneous materials that behave 
like springs.  Applying a force to the solid induces a deformation.  Upon removal of the 
force, the solid returns to its original shape (Figure 2.1a).  This behavior can be described 
by the restoring force of the spring F = -kx.  The restoring force (F) is in the opposite 
 
Figure 2.1.  A) Mechanical response of ideal solids to imposed 
stress with equations representing Hooke’s law, B) response of 
ideal liquids with equation representing Newtonian fluids, and C) 
example response of viscoelastic material exhibiting characteristics 
between solids and liquids with equation for Voigt model.  σ : 
stress, γ : strain, γ& : strain rate, η : viscosity, k: spring constant, μ : 
modulus, E : Young’s modulus 
A) 
B) 
C) 
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direction of the imposed deformation (x) and the magnitude of the force depends on 
material properties of the spring, which are defined by the spring constant (k).  Because 
samples are often different sizes, it is essential to look at the forces relative to sample size 
in order to isolate the material properties.  For this, we examine the stress (σ, force per unit 
cross-sectional area) that is proportional to strain (γ, a dimensionless measure of 
deformation).  Higher strains create higher stress in the material, or application of higher 
stresses creates larger strains.  The proportionality of stress and strain contains information 
regarding the material properties and is named Young’s modulus, or the elastic modulus 
(E). 
 For ideal or Newtonian liquids, it is helpful to think of water flowing through a pipe.  If 
you apply a force to it, water flows along the pipe.  If you stop applying a force, then flow 
stops.  There is no restoring force causing the water to return through the pipe (Figure 
2.1b).  In this case, the amount of deformation is dependent on how long the force is 
applied; the force is proportional to the deformation rate.  As we increase the stress on the 
liquid, it deforms at a higher strain rate (γ& ), or if we increase the strain rate, we increase 
the stress in the liquid.  The material properties governing this relation are defined in η, 
which is the viscosity of the liquid.  Under the same stress, a more viscous liquid (honey) 
flows slower than a less viscous liquid (water). 
Most materials cannot be accurately described by either the ideal solid or ideal liquid, but 
are more appropriately described by a combination of these.  Silly Putty™ demonstrates the 
combination of elastic and viscous properties.  If you throw a ball of Silly Putty against the 
floor it will bounce up retaining its normal shape.  During the interaction with the floor, it 
 II-5
acts like a solid, deforming as it hits, but using a restoring force to bounce back.  If you 
slowly pull on Silly Putty it will stretch and elongate.  When you stop pulling, the Silly 
Putty has flowed or creeped and will not return to its original shape.  Materials such as Silly 
Putty, which behave like solids under some conditions and liquids under others, are 
classified as viscoelastic. 
The cornea and sclera are viscoelastic materials that typically exhibit elastic behavior while 
under physiological stresses.  However, under normal intraocular pressures, the cornea and 
sclera creep in keratoconus and degenerative myopia.  This creep is what results in the 
corneal bulging and axial elongation characteristic of the diseases.  Characterization of the 
elastic and viscous properties of the tissues is essential for understanding the diseases and 
developing appropriate treatments. 
2.3 Techniques in the Field 
The ability to characterize the mechanical properties of biomaterials lies in the ability to 
make measurements of the material response to stress and strain.  Typically, this is done by 
applying one (e.g., stress) and recording the other (e.g., strain or strain rate).  The way in 
which this is done depends in large part on the type of behavior that is being analyzed.  The 
bones and spinal column bear compressive forces due to the weight of the body, tendons 
are subjected to cyclic tensile stresses, the skin is stretched over the body, blood vessels 
expand and contract with the pumping of blood, and bones shear past one another in the 
joints.  Because of the variety of forces and deformations to study, there are many 
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techniques used in biomechanics (Figure 2.2).  Also, some testing techniques are 
developed specifically to replicate the in vivo conditions. 
 
In vivo, the eye is subject to an intraocular pressure that keeps the cornea and sclera 
stressed.  In order to relate this natural state of the eye to types of mechanical testing we 
can do, it is useful to introduce the Young-Laplace equation (Figure 2.3).  The Young-
Laplace equation describes the surface tension (γ) of a membrane that experiences a 
pressure differential (ΔP) across the two sides of the membrane.  The curvature of the 
membrane at any point can be described by the radius of curvature (Rx or y) along the x- or 
Figure 2.2.  Some example methods and geometries used in 
biomechanics.  Compression—samples are sandwiched between 
plates (e.g., bone).  Uniaxial Extension—samples are stretched along 
one axis (e.g., tendon, ligaments).  Biaxial Extension—samples are 
stretched along two axes (e.g., skin), or as in arterial wall 
experiments, pressure is used to expand the blood vessel.  Shear—
samples are sheared between two plates (e.g., mucus), and some 
geometries mimic the naturally occurring curvature (e.g., joints, 
cornea).  Torsion—samples are torqued along an axis (e.g., vessels, 
bone). 
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y-axis.  By approximating the eye as a sphere (Rx = Ry = Rs), we are able to simplify 
this expression to relate the stress in the cornea and sclera to the intraocular pressure (IOP), 
knowing the radius and thickness of the eye.  In a human eye with intraocular pressures of 
18–25 mmHg, radius ~12.5 mm, and thickness ~1 mm the biaxial stress would be 15–21 
KPa.  When considering the strip geometry used in uniaxial extension, people often convert 
this to a tensile force determined by the stress and cross-sectional area of the sample.  
Samples with a width of ~5 mm and a thickness of ~1 mm have a 5 mm2 cross-sectional 
area, giving a tensile load of 0.075–0.10 N. 
 
 
Figure 2.3.  The Young-Laplace equation to describe the pressure differential 
(ΔP) across a curved membrane with surface tension (γ) can be used to 
approximate the stresses that occur in an eye.  By assuming the eye is a spherical 
shell with (Rx = Ry = Rs), the relation of intraocular pressure (ΔP), radius (Rs), and 
thickness (t) can be used to determine stresses (σ).  This relation becomes useful 
for the comparison of biomechanical testing methods. 
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Cutting tissue samples for biomechanical testing removes the intraocular pressure and 
natural stress from the specimen.  Groups often condition samples to restore the specimen 
to a state similar to in vivo.  For example, application of a pre-stress equivalent to that 
calculated using the Young-Laplace equation is used as a physiological starting point for 
measurements.  A load (e.g., ~0.1 N) is applied for a specified time and the tissue extends 
under this stress.  Unfortunately, the stress distribution in uniaxial tension (where this 
method is often used) is different than that in biaxial tension and cannot properly simulate 
in vivo conditions.  Another method of conditioning the specimens is the application of 
cyclic stresses to realign molecules within the sample, and in tensile tests it is often 
repeated until the hysteresis in the stress-strain curves disappears.  Removal of hysteresis 
implies that the stresses are large enough to cause structural changes in the specimen. 
While the application of cyclic stresses is used to precondition tissue, application of small 
oscillatory stresses can be used to probe the tissue without generating structural changes.  
Small deformation oscillatory shear rheology oscillates the tissue around zero stress and 
zero deformation (Figure 2.4).  The components of the measured shear stress and strain that 
are in phase contribute to the magnitude of the storage modulus (G′), which is related to the 
elastic properties of the tissue.  The components that are out of phase contribute to the 
magnitude of the loss modulus (G′′), which is related to the viscous properties of the tissue.  
If the stress and strain were large, it would be possible to monitor the structural changes of 
the specimen, however the use of small stresses and deformations allows gentle probing of 
the tissue. 
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2.4 Strengths and Limitations of Alternative Techniques: Illustration in Cornea and 
Sclera 
An ideal goal of mechanical measurements would be to monitor the properties of tissue 
while under physiological conditions and stresses.  The cornea and sclera are under stress 
due to the intraocular pressure of the eye, which results in tension of the tissue.  During 
blinking the cornea experiences shear forces, and during eye movement, the sclera 
experiences shear, compression, and tension.  When looking at the mechanical behavior of 
cornea and sclera, the majority of literature focuses on uniaxial tensile measurements.  
While this method has its use, other methods such as shear rheology and biaxial expansion 
can be used to further understand these tissues.  In this section, we discuss some of the 
limitations and advantages of each method and how it applies to the particular problem of 
studying cornea and sclera.  
 
 
Figure 2.4.  Oscillatory shear about a zero stress and zero 
deformation provides a method to characterize the elastic and 
viscous properties of tissue.  The material properties given in the 
storage modulus (G′, elastic property) and loss modulus (G′′, 
viscous property) govern the relationship of stress (σ), strain (γo), 
and frequency (ω).   )]cos()sin([ tGtGo ωωγσ ′′+′=  
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2.4.1 Uniaxial Tensile Tests 
Extensive literature on tensile tests of cornea and sclera provides the majority of knowledge 
regarding the mechanical properties of these tissues.1-23  However, there are surprising 
differences between research groups’ reported stress-strain curves and modulus values 
(e.g., Figure 2.5).  Modulus values for human cornea were reported from 3.81±0.40 MPa 
by Zeng2, up to 57±4.1 MPa by Andreassen.3  Friberg has reported values for human sclera 
that differ from 2.9±1.4 MPa for anterior sclera and 1.8±1.1 MPa for posterior sclera7, and 
Wollensak reported values as high as 22 MPa.22  The differences in modulus values are due 
to differences in the particular measurement techniques and protocols used.  While tensile 
measurements appear straightforward—cut a rectangular strip of tissue and apply tension—
the variations in the sample preparation, clamping, pulling, stress history, and hydration all 
play a role in the experimental outcome. 
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Much of the variability comes from the difficulties associated with loading samples.  The 
tissue hydration is important to consider, as tissue stiffness decreases as hydration 
increases, and swollen tissue may be more prone to failure.  Different methods employ the 
use of dry or moist atmospheres, saline baths, and oil baths as ways of controlling the 
hydration. 
In order to apply tension to the samples, the ends must be secured.  Methods of securing the 
samples include clamping, gluing or pinning.  Challenges associated with clamping result 
from slip of the sample in the grips and tissue damage near the ends due to deformation 
inherent in clamping.  Challenges associated with glues include modification of tissue 
properties produced by glue that diffuses into the tissue and hardens.  Lastly, pins cause 
further damage to the already cut samples.  With all three fastening methods, further 
Figure 2.5.  Results from (A) Hoeltzel1 and (B) Zeng2 showing the stress-strain response 
of human cornea after cyclic conditioning.  Hoeltzel demonstrates that 3 cycles removes 
hysteresis from the testing and Zeng shows results after 3 cycles.  Note that results from 
Hoeltzel range from 0–7% strain and 0–0.5 MPa stress while Zeng ranges from 15–40% 
stress and up to 3 MPa.  This is exemplary of the vast differences that exist in current 
literature regarding mechanical testing of cornea and sclera. 
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uncertainty in the measurement results from variability in configuration of the tissue 
between the fixtures.  Ideally, the sample should be parallel to the direction of tension, and 
neither slack nor taut at the point of zero extension. 
Unfortunately, samples are often slack upon loading, so there is uncertainty of the true 
length of the tissue.  Several methods have been used to provide a self-consistent zero 
extension point for a set of measurements.  For example, common practices include 1) 
alignment of data, 2) pre-stressing, and 3) minimal initial stress.  Alignment of data uses 
features in the stress-strain curve (such as the elbow region) as registration points among a 
data set to shift individual curves on top of each other.  After the curves are aligned, a zero-
extension point is selected.  Pre-stressing a sample involves imposing a specific, small 
stress for a specified time, after which the desired test condition is imposed (typically a 
specified crosshead speed or a specified load that is greater than the pre-stress load).  The 
length at the end of the “pre-stress period” is taken to be zero extension and calculations of 
strain during the experiment relative to that length.  The “minimal initial stress” method 
uses the extension at which the stress reaches a small, specific value during tension as the 
zero-extension point.  In the experiments below, the minimal initial stress method was 
used. 
The variability in loading methods, tissue preparation, and testing procedures all add to the 
uncertainty of results.  The following experiments examine the variability of data that is 
seen under conditions that minimize the variability, namely low stress (< 1 MPa) and low 
strain (< 20%). To place the observed uncertainty in context, we compare two groups of 
specimens: sclera specimens held for 12 hours in saline (making them somewhat softer 
 II-13
than their initial state) and specimens held for 12 hours in glyceraldehyde solution 
(making them much stiffer than their initial state).  The experiments demonstrate the 
inability of this method to characterize the changes that result from fairly extreme 
crosslinking with glyceraldehyde. 
Method:  Eyes from 3–4 month old swine were ordered from Sierra for Medical Science 
and stored in saline on ice until use within 72 hours post mortem.  Orbital tissues were 
removed and strips of either 3 or 5 mm width and approximately 20 mm length were cut 
from the cornea or the posterior sclera using parallel scalpel blades.  The strips of cornea 
ran from superior to inferior across the center of the cornea (Figure 2.6a).  The cornea was 
~14 mm in length, and surrounded on each side by ~3 mm of sclera.  The strips of sclera 
ran superior to inferior and were temporal to the optic nerve (Figure 2.6b).  The control 
samples were stored in Dulbecco’s phosphate-buffered saline (DPBS), while the treated 
samples were stored in a 2% glyceraldehyde solution (GA).  After 12 hours in solution at 
room temperature, the samples were tested on an Instron 5542 Universal Materials Testing 
Machine (Instron Corp., MA).  The tissue sections were laid across the 6 mm gap of the 
testing apparatus as shown in Figure 2.7.  To prevent slippage of the sample, pieces of 
Kimwipe were placed between the sample and the metal clamp, providing a higher friction 
surface.  A permanent marker was used to mark where the tissue touched the clamp, and 
was observed for any movement that would indicate slip.  After clamping, the samples 
were loaded vertically into the Instron and pulled at a rate of 1.0 mm/min (cornea) or 1.5 
mm/min (sclera) while recording the stress.  The samples were in air at ~48% humidity and 
~20 ºC.  The instrument stopped pulling when a maximum load of 5 N was reached.  Zero 
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extension was taken as the point where the instrument first recorded a non-zero 
apparent stress (0.005 MPa = F/A, where F is the measured load and A is the initial cross-
sectional area) in the sample. 
  
Figure 2.6.  Strips of tissue were cut from porcine eyes using 
parallel scalpel blades.  A) The section of cornea was ~14 
mm long within a ~20 mm section cut from superior to 
inferior, containing the center of the cornea.  B) The section 
of sclera was ~20 mm long and cut from the posterior globe 
running from superior to inferior, temporal to the optic 
nerve.  The strips were either 3 mm or 5 mm in width and 
thickness varied from 0.83–2.06 mm depending on the 
animal. 
A) B) 
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Results: Stress-strain curves of the scleral strips show large variability between different 
sections, as depicted in the scattered curves of control data (Figure 2.8a, b).  Curves from 3 
mm sections exhibit more scattering than those of 5 mm sections, but still exhibit a 
similarly shaped curve.  The experimental soak with GA is extreme and generates changes 
in the tissue that are observable by eye and touch (tissue sections have browned and hold a 
curved shape during loading).  It is expected that tensile tests would measure such 
differences, however, plotting the average results shows that there is no difference between 
Figure 2.7.  Tissue sections were mounted for 
testing on an Instron 5542.  The specimens were 
laid across a 6 mm gap and clamped securely.  
Kimwipe between the clamps and tissue provided 
enhanced friction to prevent slipping.  The clamp 
fixture was mounted vertically on the Instron and 
pulled at 1.0 mm/sec (cornea) or 1.5 mm/sec 
(sclera) while the force transducer recorded the 
load. 
 II-16
the treated and control groups (Figure 2.9).  In fact, the only significant difference is 
exhibited in low strain (0–5%) where the 2% GA sections have less stress at the same strain 
as controls (significance determined from t-tests with p values p < 0.05).  These results are 
contrary to observation and contrary to the known effects of GA.  Because of the large 
variability that results from cutting, loading, clamping, and testing of samples, this method 
is not able to measure the change in modulus that results from GA treatment.  This GA 
treatment would be more extreme than treatments planned for use in keratoconus or 
degenerative myopia.  Because of the inability of this method to monitor large changes in 
treated tissue, other methods of characterizing tissue are discussed in the sections below.  
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Figure 2.8.  Plots of apparent stress-apparent strain curves of individual porcine sclera 
sections showing the results of incubations in DPBS or GA for 12 hours prior to 
measurement.  There appears to be greater scatter in 3-mm-wide sections than in 5-mm-
wide sections, and all curves show similar responses to strain. 
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Figure 2.9.  Averages of results displayed in Figure 2.8 indicate that there is no 
measureable difference in GA crosslinked sclera and control sclera.  Although t-test results 
indicate that the GA treatment results in less stiff sclera for strains 0–5%, this does not 
remain so for higher strains and is contrary to physical observation.  These results are 
unreliable even when comparing groups of size n = 11 and 12. 
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The measured stress-strain curves for cornea are typical of those reported in literature 
and the graphs in Figure 2.10a demonstrate similar curves as in Figure 2.5.  Out of 8 cornea 
strips tested, 5 did not have problems from loading, and individual curves are shown in 
Figure 2.10b.  Cornea 2 shows little increase in stress above 10% strain, indicating either 
slippage, or failure of the tissue.  Cornea 6 shows a bump at 17% strain which could also be 
explained by tissue slippage or failure.  Although no signs of slippage could be seen from 
movement of the markings on the cornea, the individual curves indicate possible slippage.  
There is no way to determine if this is truly slip, so the data cannot be disregarded.  With 
this in mind, the average and standard deviation that is displayed in Figure 2.10a could be 
unreliable and gives us uncertainty in the reliability of results published in literature.  The 
same results are presented in Figure 2.11 with stress on a log scale.  This scaling method 
allows examination of behavior at small strains, comparison to the porcine data, and it 
reveals that the scatter is increasing with strain rather than remaining a constant percentage 
of the stress.  This scatter observed here is similar to the scatter reported for cornea in the 
introduction of this section. 
Further examination of the variability due to different loading methods (specifically 
different prestresses) is easy to do using our extension curves.  By changing the “minimal 
stress” used as a threshold for calculating zero extension, we change the observed curves 
(Figure 2.12).  The curves become steeper and the tissue undergoes less strain before 
failure.  The steepness of the curves is related to the elastic modulus, and from this example 
it is possible to see how having a higher prestress results in higher modulus values.  The 
range of reported modulus values in literature can in part be attributed to the differences in 
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prestress and loading techniques.  It would be useful for future researchers to study the 
relative merit of different methods of securing samples and determining the initial sample 
length. 
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Figure 2.11.  The same results presented in Figure 2.10 are shown here on a log scale.  
This scaling method helps demonstrate that scatter is increasing with increasing percent 
strain. 
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Figure 2.10.  A) The average results of tensile tests for 5-mm-wide cornea sections (n = 5) 
reveal stress-strain relations similar to those reported in literature (Figure 2.5).  B) The 
plots of individual curves (5 out of 8 corneas) indicate the variability of this method, as 
well as the potential slippage of samples.  Because no slipping was visibly observed, these 
samples have all been included in the average. 
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2.4.2 Oscillatory Shear Rheology 
Shear provides complimentary information to elongation tests.  Both the cornea and the 
sclera may be viewed as fiber-reinforced composites in which relatively tough, inextensible 
collagen fibrils are embedded in a soft hydrogel matrix.  The fibrils are preferentially 
oriented in the plane of the tissue, with a greater degree of alignment in cornea than in the 
sclera.  Under tension, the stress buildup occurs in fibers, while under shear the fibers are 
more prone to slide past one another.  Therefore the apparent rigidity of the tissue is 
expected to be greater under tension than in shear.  This hypothesis is referred to in 
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Figure 2.12.  Changing the “minimal stress” or “prestress” that is used to 
calculate zero extension changes the stress-strain curves.  Using the 
results of porcine sclera, we demonstrate the effects of changing the 
initial stress threshold from 0 to 0.1 MPa.  As the prestress increases, 
curves become steeper, indicating higher modulus values. 
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literature about modeling the cornea and sclera24, but there is limited literature which 
tests this hypothesis25. 
Unfortunately, many of the sources of uncertainty encountered in tensile testing above are 
also confronted using shear; there are inherent difficulties in keeping tissue properly 
hydrated, avoiding structural damage while loading and testing, and imposing a well-
defined deformation to a slippery specimen.  Here we use a thermostated bath to control 
tissue hydration.  We use a sample of radius 4 mm to analyze specimens cut from porcine 
eyes of radius 12 mm, so that only small deformation is required to load the slightly dome-
shaped specimen into the disc-shaped geometry of the rheometer tools (Figure 2.13).  To 
prevent slip, cleated tools developed in our laboratory26-29 are employed, providing superior 
results compared to smooth plates, roughened plates, or grooved plates.  With these 
methods, reproducible measurements of the dynamic moduli were obtained.  That is, 
oscillatory shear was imposed with such a small strain amplitude that the deformation did 
not perturb the structure or properties of the tissue.  The present method allows for repeated 
measurement of storage modulus on the same scleral section (e.g., before and after 
crosslinking), and also enables in-situ monitoring of environmental effects on the modulus 
(e.g., effects of NaCl concentration, pH, and temperature). 
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Materials: Dulbecco’s phosphate-buffered saline (DPBS) was purchased from Sigma 
Aldrich (pH 7.5, 0.9% NaCl).  Solutions of varying salt concentration (0–2% by weight) 
were prepared by mixing NaCl in deionized water and adjusting the pH to 7.5 using NaOH 
or HCl.  A series of 0.9% saline solutions with pH ranging from 5 to 10 were prepared 
from 10 mM PBS buffer—4 g NaCl, 0.72 g Na2HPO4, and 0.12 g NaH2PO4 (Sigma 
Aldrich) dissolved in distilled water for a final volume of 500 mL—with pH adjusted using 
NaOH or HCl. 
Porcine eyes were acquired from Sierra for Medical Science and were stored in 0.9% saline 
on ice until use within 72 hours of enucleation.  The fat and muscle from all eyes were 
removed with scissors to expose the sclera.  An equatorial incision was used to separate the 
posterior sclera from the anterior hemisphere of the eye.  The vitreous, retina, and choroid 
were removed and 8 mm circular sections were cut using a trephine punch (Katena).  The 
center of the circular section was located ~10 mm from the optic nerve and in some cases 
Curved strip for extension Curved disk for shear
Figure 2.13.  Strips cut for either tensile or shear measurements must be straightened 
before testing.  Straightening the tissue introduces stresses in addition to those imposed 
by the measurement technique. 
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multiple sections were cut from one eye.  The following studies used approximately 
60 eyes. 
Procedures: Circular sections were tested in an 8 mm parallel plate geometry modified 
with cleats on an AR1000 (TA Instruments) Stress Controlled Rheometer (Figure 2.14).  
The sample was placed on the lower geometry, and then the upper geometry was lowered 
to contact the sclera.  Experiments monitoring the effect of normal force and tissue 
compression on the modulus were used to determine the appropriate forces to achieve good 
contact (Figure 2.15).  Good contact was made when the instrument registered a 0.1 N 
normal force.  The tool position is then fixed and the gap between the tips of the cleats on 
the two tools was used to compute the shear strain from the observed torsional 
displacement.  A small oscillatory stress was imposed on the sample such that the native 
structure of the tissue was not perturbed.  The amplitude and phase of the resulting 
oscillatory deformation reveal the elastic and dissipative character of the material, which is 
typically a function of the frequency of the imposed oscillation. The elastic character of the 
tissue is manifested in the storage modulus, G′(ω).  Because the sclera is solid, at low 
frequency its behavior is primarily elastic and the modulus becomes insensitive to 
frequency.  Oscillatory shear measurements were done using a stress amplitude of 5 Pa and 
a frequency of 1 rad/sec.  Temperature was controlled using a Peltier plate and the solution 
surrounding the tissue was prevented from evaporating by using a solvent trap.  The solvent 
trap had a port that could be accessed to change the solution around the tissue. 
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Figure 2.14.  Rheometry system for characterizing ocular 
tissues.  An 8-mm-diameter disc-shaped specimen, is loaded 
between parallel disc cleated tools.  Significantly, the cleated 
tools are loaded without the application of significant 
normal force or compression of the tissue.  A chamber 
around the sample is used to control the environment 
(appropriate saline solution).  Temperature is controlled 
from below with a peltier plate.  The tools and chamber are 
used on a stress rheometer (TA Instruments AR1000). 
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Figure 2.15.  Modulus values increase as tissue is compressed.  At low compression, the 
tissue is prone to slip, while at high compression residual stress builds in the tissue, 
artificially increasing the modulus.  Loading with a normal force of ~0.1 N compresses the 
sclera by 30 ± 4.3 % (n = 12) and compresses the cornea by 35 ± 1.6 % (n = 3).  These 
regions of compression are indicated in the highlighted boxes on each of the graphs.  
Tissue was compressed to this point in order to ensure good contact and reliable modulus 
measurements without tissue slippage. 
10 Pa, 1 rad/sec 5 Pa, 1 rad/sec 
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Samples were tested using two different methods.  First, the gentle nature of our 
loading protocol allows samples to be characterized pre- and post-incubation: with 
negligible damage, each sample can be loaded, measured for initial modulus, unloaded, 
incubated in a treatment solution, and measured on the rheometer again.  Second, the 
effects of salt, pH, and temperature on the modulus were measured in situ while leaving the 
sample loaded. 
GA crosslinking:  Using the incubation method, tissue sections were tested for changes in 
modulus due to GA crosslinking by measuring an initial modulus, soaking the tissue for 24 
hours in 2% GA, measuring the modulus after treatment, rinsing for 24 hours in DPBS, and 
then measuring the modulus after treatment. 
NaCl concentration:  Testing for the effects of salt concentration was done using both an 
incubation protocol and an in situ transient protocol.  For the incubation protocol, samples 
were soaked in DPBS for 24 hours, measured for initial modulus, incubated in 0–2% NaCl 
(pH 7.5) for 24 hours, and then measured for final modulus.  An in-situ measurement of 
NaCl effects was conducted by continuously measuring the modulus while the bath fluid 
was changed (0–60 min 0.9% NaCl, 60–120 min 0% NaCl, 120–180 min 0.9% NaCl). 
pH:  The effects of pH on the scleral modulus were determined using both an incubation 
protocol and an in-situ protocol.  The incubation method consisted of soaking samples in 
DPBS for 24 hours, measuring initial modulus, incubating in a 10 mM PBS solution of a 
selected pH (5, 6, 7.4, 8, or 9) for 24 hours, and then measuring a final modulus.  In-situ 
measurement of pH dependence was done by continuously measuring the modulus while 
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changing the surrounding solution (0–120 min DPBS at pH 7.5 and 120–140 min, 10 
mM PBS of a selected pH [5, 6, 7, 7.4, 9, or 10]). 
Temperature:  Temperature dependence was monitored in situ by continuously measuring 
the sclera at 37ºC for 1 hour, lowering the temperature to 5ºC for 1 hour, and raising the 
temperature back to 37ºC for the final hour. 
Results: The initial storage modulus of pig sclera as measured using a stress amplitude of 5 
Pa and frequency of 1 rad/sec is 4500 ± 1400 Pa (n = 66 specimens cut from 22 eyes) in 
DPBS at 37ºC.  While our measurements of shear modulus were on the order of 5x103 Pa, 
measurements of Young’s modulus are of the order of 106 Pa for sclera (previous section).  
In contrast to homogeneous isotropic materials, which have tensile modulus E only 3-fold 
greater than their shear modulus G, the sclera show E ≈ 100G consistent with the known 
structural anisotropy and inhomogeneity of the tissue noted earlier.  While fibers are able to 
slide past one another in shear, the resistance to this motion arises from the components 
between collagen fibers and bundles (glycosaminoglycans, proteoglycans, and collagen 
connectors).  Shear has the potential to provide information regarding the interaction of 
these components and how they contribute to strength. 
GA crosslinking:  Although the change in Young’s modulus upon crosslinking with 
glyceraldehyde could not be successfully measured using tensile tests, shear measurements 
readily reveal an approximately 3-fold increase in modulus after a 24 hour incubation 
period (328 ± 112.0 % increase in G′, Figure 2.16, left).  In contrast, the control specimens 
are slightly softer after their 24 hour incubation in DPBS.  After a further 24 hour rinse in 
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DPBS, the modulus continues increasing to 379 ± 133.1 % of its original value.  The 
reason that GA crosslinking continues even after free glyceraldehyde is extracted and its 
implications regarding a clinical procedure are discussed in Chapter 3.  The control 
specimens show a small further softening following their second 24 hour incubation in 
DPBS (Figure 2.16, right). 
 
NaCl concentration:  The effect of the salt concentration in the incubation solution on the 
change of modulus is pronounced at low salt concentrations (Figure 2.17).  In particular, 
the shear modulus increases at least 4-fold when specimens are incubated in solution with 
≤0.1% salt for 24 hours.  Control eyes in DPBS show a slight decrease in storage modulus 
(28 ± 8.0%) upon the second measurement 24 hours after the first.  Increasing the salt 
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Figure 2.16.  Glyceraldehyde crosslinking of sclera for 24 hours 
increases the modulus over 300% while control values slightly 
decrease.  Even after rinsing residual glyceraldehyde from the 
tissue, crosslinking continues increasing the modulus over the 
next 24 hours. 
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concentration causes an asymptotic decrease in modulus, reaching a 50 ± 1.0% 
reduction in modulus at 2% NaCl. 
In-situ measurements of shear modulus when the NaCl concentration is changed from 0.9% 
to 0% and back to 0.9% (Figure 2.18) demonstrate that change in modulus is reversible.  In 
addition, the transient effect seen after changing the solution from 0.9% to 0% appears to 
plateau after ~1 hour.  The transient effect upon replacing the 0.9% NaCl solution occurs 
rapidly, with most of the effect occurring within 30 minutes.  Permeability of the bovine 
sclera to sodium ions is large (4.6 x 10-5 cm/sec),30 and the transient response seen in the 
porcine sclera is likely due to diffusion of ions in and out of the tissue.  The change in 
modulus is not accompanied by a change in normal force, which would indicate swelling of 
the bulk tissue. 
The changes in modulus that occur with changes in salinity are most likely explained by the 
electrostatic screening effects of salt on the highly charged molecules within the sclera.  
Glycosaminoglycans are repeating units of disaccharides and are highly charged.  
Proteoglycans are protein cores with attached glycosaminoglycan chains.  These molecules 
may be considered flexible while in high salinity, but as free electrolytes are removed, the 
glycosaminoglycan side chains expand, causing the proteoglycans to take on a stiff, “bottle 
brush” like conformation.  Grodzinsky has proposed that the stiffening of molecules within 
the tissue (e.g., cartilage or sclera) would create stresses that are manifested as an increase 
in modulus.31 
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Figure 2.17.  All samples were initially measured in DPBS 
at 37ºC and then placed in their respective salinity solutions 
for 24 hours.  The % change is calculated for each 
specimen with % change = (G′final- G′initial)/ G′initial*100.  
Variability from specimen to specimen was large (G′initial = 
4500 ± 1400 Pa for n = 60 samples from 20 eyes) 
compared to the reproducibility of the change in modulus 
for each specimen. 
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Figure 2.18.  In-situ measurement of changing salt 
concentration shows the rapid change in modulus 
associated with ions diffusing into the sclera.  The ~6-fold 
change in modulus from ~8,000 Pa to ~55,000 Pa falls 
within the range of values measured for incubations in 
~0% solution.   
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pH:  Electrostatic interactions of the constituent molecules are also influenced by 
changes in pH.    Incubations of scleral discs in different pH solutions yield results given in 
Table 2.1.  Increasing the pH does not cause any measurable differences as compared to 
controls at physiological pH of 7.4.  However, decreasing the pH causes stiffening of the 
tissue, with a 48 ± 40.1% increase in modulus at pH 5.  Note that the uncertainty present at 
pH 7.4 contains variability of reloading, as well as sample-to-sample variability.  The 
uncertainty of these measurements is large compared to the changes and makes conclusive 
observations difficult. 
% Change pH Avg ± Stdev 
# of 
Samples 
5 48 ± 40.1 9 
6 44 ± 68.4 6 
7.4 -21 ± 23.6 6 
8 -24 ± 17.1 9 
9 -24 ± 19.3 6 
Table 2.1: 24 Hour Incubation Experiments  
 
In-situ measurements remove the error associated with reloading a sample and definitively 
show the effects of altering the pH.  Lowering the pH increases the modulus while 
increasing the pH has little effect on the modulus (Figure 2.19).  Within two hours, there is 
no change in modulus at pH 7.4, 9, or 10.  Although the modulus does not reach a plateau 
value within the 2 hours of this test, lowering the pH to 6 increases the modulus by 18 ± 
5.4% and lowering to 5 increases the modulus by 62 ± 12.8%.  Based upon diffusion of 
ions in the NaCl studies, we would expect the transient response for pH changes to also 
near completion within 1 hour.  Because the transient timescale is more than twice as long, 
we hypothesize that some form of remodeling occurs in the sclera.  However, the modulus 
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changes were reversible for all tested pH values, and Figure 2.20 demonstrates the 
reversibility with pH 7.4, 5, and 9. 
The pKa of sulfate, carboxyl, and amine groups that are relevant to proteoglycans and 
collagen in the cornea and sclera are 2–2.532, 4.133, and 9.333 respectively.  As pH 
approaches these values, we expect to see changes in the mechanical properties.  While we 
would expect large effects close to these values, it is interesting to notice that there is no 
response when passing the pKa for amines.  At lower pH, the sulfate and carboxyl groups 
are expected to become protonated, reducing charge in the tissue.  A reduction in charges 
could reduce the stress of the molecules in the tissue and reduce the modulus, so the 
increase in modulus at pH 5 and 6 is counterintuitive.  Future research into the interactions 
within the sclera is necessary to explain these results. 
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Figure 2.19.  Changing solutions from (A) DPBS to (B) a 
different pH causes changes in modulus for decreasing pH.  
These values do not plateau within 2 hours, in contrast to 
the plateau near 1 hour seen in NaCl tests. 
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Temperature:  Cooling of samples from 37ºC down to 5ºC causes more than a 60% 
increase in modulus (Figure 2.21).  This finding is in agreement with prior literature 
regarding the softening of tissue with increasing temperature.25, 34 
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Figure 2.20.  While decreasing the pH 
from 7.4 to 5 causes an increase in 
modulus, increasing the pH around the 
same sample from 5 to 9 causes a 
decrease in modulus.  This demonstrates 
that pH in this range has not permanently 
altered the sclera.
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In-situ monitoring helps eliminate some of the variability associated with repeated loading 
and unloading of a sample, and provides a more accurate method to study the effects of 
environmental factors on the tissue.  Shear measurements are subject to similar variability 
of cutting and loading specimens as tensile tests.  This is clear from the large scatter in 
initial modulus measurements (G = 4500 ± 1400 Pa).  The ability to non-destructively 
measure and remeasure samples provides a way to remove some sample-to-sample 
variability.  Samples used for measurements of NaCl concentration effects show 
remarkable similarities in % change.  Changing from repeated measurements to in-situ 
monitoring further reduces the variability by eliminating errors introduced by reloading the 
sample.  In-situ monitoring very clearly shows the time course of changes that happen in 
individual specimens. 
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Figure 2.21.  The modulus increases as temperature is 
decreased and causes stiffening of the tissue.  Returning the 
temperature to physiological levels restores the modulus to 
its original value.
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2.4.3 Intact Globe Expansion Tests 
The uniaxial tensile tests and shear tests mentioned above do not accurately simulate the 
loading geometry that occurs in vivo.  The sclera and cornea are under tension due to the 
IOP, which imposes an approximately biaxial stress, not a uniaxial one.  Shear stress can be 
imposed during blinking and eye movement, but it is in addition to the biaxial tension that 
is constantly acting on the cornea and sclera.  To more closely mimic the physiologic 
stresses, researchers have used button and intact globe expansion tests.34-49 
Button tests consist of removing a portion of the eye and clamping it to a pressurizable 
chamber (Figure 2.22a).  The clamps around the specimen periphery are to ensure a fixed 
boundary condition as the interior surface expands under pressure.  Because of the cutting 
and mounting of specimens, this method has disadvantages similar to the tensile and shear 
tests. 
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Intact globe expansion experiments use the eye without cutting the tissue (Figure 2.22b).  
The fibril structure is not disturbed by cutting or clamping, and there is an attempt to 
maintain the natural boundary conditions of the eye.  Most importantly, the type of stresses 
imposed in this intact globe expansion test provide a model for conditions that more closely 
resemble in vivo stresses.  Some research groups have glued eyes to fixtures, or pierced 
eyes with several needles in order to hold them steady while testing.  In our experiments, 
whole eyes are set upon a ring support and pierced through the posterior pole with a single 
needle that is used to control IOP.  In this manner, there is only minimal damage at the site 
of the needle.  The eyes are not clamped or glued to the ring support, so they are free to 
expand along any ocular dimension.  To measure ocular dimensions, groups have used 
lasers, interferometry, ultrasound, calipers, and photography.  With current advances in 
 
Figure 2.22.  A) Buttons of tissue cut from the 
eye are mounted on a fixture with a circular hole 
that allows tissue to expand outward.  The tissue 
is clamped down and the pressure inside the 
fixture is elevated to cause expansion.  B) The 
entire eye is kept intact and a needle is inserted 
to control intraocular pressure. 
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technology, cheap cameras are able to provide high-resolution images (~28 
micron/pixel in this study) and even video.  Using this method, we are able to keep the eye 
submersed in a physiological bath and remotely monitor the shape change.  By minimizing 
tissue disturbance, variability is reduced to that associated with animal-to-animal 
variability.   
In degenerative myopia and keratoconus, there are shape changes that occur gradually 
under a normal intraocular pressure.  While creep occurs in the weakened, diseased tissue 
in vivo, we are able to use intact globe tests to induce creep of cornea and sclera by 
imposing elevated intraocular pressures in distensible rabbit eyes in vitro.  By inducing 
creep, we are able to study the deformation of the tissue, and are able to study treatments 
for their ability to prevent deformation.  We demonstrate eye creep at low and high IOPs 
and demonstrate stabilization of eye shape using crosslinking with GA. 
Materials: Eyes from New Zealand White rabbits were provided by Keith Duncan at 
University of California, San Francisco.  Because young eyes are more distensible 
(collagen fibrils are not completely matured), we have used rabbit kit (2–3 weeks old) 
globes for these experiments.  The eyes were stored in saline on ice until use within 48 
hours of enucleation.  The fat and muscle from all eyes were removed with scissors to 
expose the sclera.  Twelve rabbits were used in this study. 
Procedures: Enucleated eyes used for the study of elevated pressure and creep were placed 
in DPBS at room temperature (~22ºC) for 30 minutes prior to loading.  GA crosslinking 
was done by removing the corneal epithelium, soaking for 12 hours in 2% GA, rinsing for 
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12 hours in DPBS, and then loading.  Eyes were loaded in a transparent plexi-glass 
observation cell filled with DPBS.  The eyes were aligned with the major axis of the 
equator parallel to the imaging plane.  Two holes at the bottom of the cell were used for the 
insertion of hypodermic needles (30 gauge) that regulate the IOP (Figure 2.23b).  The 
needles were inserted into the eyes through the posterior sclera, and they were fed from a 
DPBS reservoir held a certain height h above the apparatus, thus providing an IOP 
governed by hydrostatic pressure (IOP = ρgh; ρ = density, g = gravitational acceleration).  
The eyes were equilibrated in the cell for 15 minutes without any control of IOP.  The 
pressure valve was then opened, and the eyes were maintained at an initial IOP of 22 
mmHg for 1 hour, and then maintained at either 22 or 85 mmHg for 24 hours.  Photographs 
of the eyes were taken every 15 minutes throughout the experiment and then analyzed for 
changes in ocular dimensions using MATLAB (Scleral Perimeter—SP, Equatorial 
Diameter—ED, Scleral Length—SL, Corneal Perimeter—CP, Corneal Diameter—CD, 
Corneal Length—CL, and Axial Length—AL, Figure 2.23c).  The Canon Powershot G3 
used in these experiments gave a resolution of ~28 microns per pixel.  For the 24 hours 
preceding the experiments, the DPBS was set out at room temperature so that dissolved 
gasses could escape and eliminate bubbles that interfere with measurements.  To minimize 
bacterial growth during the experiment, several antibiotic eyedrops (Bausch & Lomb 
neomycin, polymyxin B sulfate and gramicidin ophthalmic solution USP) were added to 
the solution in the observation cell. 
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Results: Because the enucleated rabbit eyes are taken from saline and loaded without 
application of pressure, they are initially in a slack, unknown configuration.  After turning 
on the low pressure (22 mmHg), the eyes have a fast expansion that takes place within the 
first 30 minutes and is mostly complete by the time 1 hour has elapsed (Figure 2.24a).  As 
an example, results for CP of 5 eyes show a jump in length from the second to third data 
points, coinciding with the application of pressure.  It is interesting to note that eyes 1 and 2 
(belonging to the same animal) have initial differences in shape that are reduced after 
pressure is applied.  The difference within animals (1&2, or 3&4) is much smaller than the 
variability of the entire group, indicating that fellow eyes provide a good control for these 
studies.  Looking at the percent change in shape from the onset of low pressure 
Figure 2.23.  A) Initial setup using mirrors for photographing an eye from multiple angles 
to give a more complete record of eye expansion.  This was traded for the simplicity of the 
setup in B) which uses a pair of eyes for internal control and a ring stand that allows free 
expansion of the eye.  C) Ocular dimensions are measured using custom MATLAB 
software. 
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demonstrates that there is large scatter in the end results, with measurements ranging 
from 6–22% after 24 hours (Figure 2.24b).  For studies of creep, which are applicable to 
keratoconus and degenerative myopia, we are interested in the changes that occur after the 
initial expansion period.  The creep is determined from the changes occurring after 1 hour 
of low pressure application (Figure 2.24c).  We see that creep of the eyes has small 
variability (0–6% change) compared to the expansion from the initial shape.  All but one of 
the eyes fall in the range of 4–6% change.  The method of applying a low pressure for a 
specified time is similar to applying a prestress in tensile tests.  However, the boundary 
conditions of a whole eye ensure the prestress is distributed similarly to in vivo stresses.  
This prestressed configuration (1 hour at 22 mmHg) is taken as the starting point for further 
analysis of creep.  Measurements of eye dimensions after 1 hour of low pressure give a 
baseline for the initial size of the rabbit eyes (Table 2.2).  Equatorial diameter (ED) is 
larger than the axial length, indicating the oblate shape of the eyes. 
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Figure 2.24.  Measurements of CP 
are illustrated for 5 eyes undergoing 
expansion at a low pressure of 22 
mmHg for 24 hours.  The pressure is 
turned on 15 minutes from the start 
of measurements.  A) Initial 
differences in size between eyes 1 & 2 
of rabbit 1 decrease with application 
of pressure, whereas eyes 3 & 4 from 
rabbit 2 already start out as similar 
size.  B) Starting calculation of % 
change from the start of low pressure 
shows similar variability as 
measurements of length.  This is due 
to the initially unknown conformation 
of the eyes.  C) Calculating % change 
from the time point 1 hour after low 
pressure provides a method of 
removing the initial uncertainty in eye 
size and eliminates scatter in the 
results. 
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Ocular Dimensions 
1 Hour at 22 mmHg  (n = 11 eyes) 
Measurement Avg. ± SD. (mm) 
SP 28.53 ± 1.270 
ED 13.78 ± 0.655 
SL 9.60 ± 0.413 
CP 12.21 ± 1.112 
CD 10.08 ± 0.802 
CL 3.00 ± 0.373 
AL 12.60 ± 0.573 
Table 2.2: Measurements of Prestressed 
Rabbit Eyes  
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After applying the initial prestress, maintaining the eyes at low pressure for up to 24 
hours induces less creep than maintaining the eyes at high pressure (Figure 2.25).  The 
cornea and sclera behave differently, as can be expected from tensile tests which 
demonstrate the sclera has a higher modulus.  At low pressure, it is apparent that the sclera 
is less susceptible to creep than the cornea (SP, ED, & SL change < 1% while CP, CD, & 
CL change 4, 2, and 10% respectively).  Together, the cornea and sclera contribute to the 
changes in AL (2%).  The changes in CP, DP, CL, and AL do not appear linear and may 
reach plateau values in a period longer than 24 hours.  For the high pressure, the creep rates 
appear linear from 8–24 hours. 
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The continuous creep experienced in the high-pressure eyes is useful for the study of 
keratoconus and degenerative myopia where we are trying to examine tissue that 
progressively changes shape.  Further, treatments that successfully prevent expansion of 
eyes due to creep could have potential as therapeutic agents.  Eyes soaked in 2% GA 
treatment became hard and yellow, indications that crosslinking had occurred.  After 24 
hours at the high pressure, none of the treated eyes expanded, while control eyes expanded 
in all dimensions (Figure 2.26). 
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Figure 2.25.  Rabbit eyes subjected to low (22 mmHg) and high (85 mmHg) pressures for 
up to 24 hours show the susceptibility of the cornea and sclera to creep.  At low pressure, 
the sclera remains stable (top row) while the cornea expands to nearly a plateau value 
(middle row).  At high pressure, the cornea and sclera both expand and the creep rate 
appears linear from 8–24 hours.  For values of the overall dimensions, refer to Table 2.2. 
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Treatments that prevent expansion of the eyes in vitro show the potential to strengthen the 
tissue and prevent distension in vivo.  Using the intact globe method, we are able to screen 
potential treatments with relatively few animals as compared to the tensile and shear tests.  
By using a test that has resemblance to physiological stresses, we are more likely to probe 
conditions that are relevant to stopping corneal and scleral shape changes in keratoconus 
and degenerative myopia.  For these reasons, the intact globe method has been chosen to 
demonstrate treatment efficacy in later chapters. 
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Figure 2.26.  Glyceraldehyde (GA) crosslinking of whole eyes stiffens the tissue and 
noticeably changes the response of the intact eyes to high pressure.  While control eyes 
expand along every dimension, the treated eyes show little expansion along any of the 
dimensions. 
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The expansion studies developed here could also find application in the study of eyes 
with altered mechanical properties.  Currently, we use the tests to induce deformation in 
normal tissue, but studies of diseased tissue may show increased susceptibility to distension 
with worsening disease state.  While this has been studied with tensile measurements, we 
believe that this method will provide a fuller characterization of the changes.  Studies of 
molecules such as retinoic acid, which is known to cause increased axial growth in chicks, 
could provide insight to the mechanisms by which changes occur in the sclera (cell 
signaling, or direct effects on collagen).  Such future work with this model is likely to yield 
new insights to the field of eye biomechanics. 
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3.1 Introduction 
Treatment of keratoconus and degenerative myopia have been proposed that aim to prevent 
tissue deformation by reinforcing the tissue, using crosslinking, which has been shown to 
increase tissue modulus and strength (Chapter 2).  Wollensak, Seiler, Spoerl, and co-
workers have developed a photoactivated crosslinking system as a potential treatment to 
arrest progression of keratoconus.1-14  Through a series of laboratory and clinical studies, 
these investigators have demonstrated the efficacy of this treatment for keratoconus, and 
examined the possibility of using this treatment for degenerative myopia.  A 
photosensitizing agent (riboflavin) is administered to the cornea then activated by 
excitation with ultraviolet light (UV-A), inducing crosslinking within the tissue.  In vitro 
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study of UV-A irradiation after treatment with riboflavin showed an increase in 
modulus greater than 3 times for human corneal strips8 and human sclera specimens.20  In 
vivo experiments in a rabbit model showed that UV-A/riboflavin treatment of the cornea 
caused a 12% increase in collagen fiber diameter, an effect that may contribute to the 
increase in corneal modulus.14  FDA clinical trials are currently underway to determine the 
safety of UV-A/riboflavin treatment for keratoconus. 
Photoactivated crosslinking systems such as UV-A/riboflavin have advantages in temporal 
and spatial control over traditional crosslinking agents or reducing sugars.  First, traditional 
crosslinkers begin to react as soon as they contact the tissue and create intermediary 
products that can continue reacting for minutes to days after removal of the excess reducing 
sugars.  This effect is evident in the additional 50% increase of the shear modulus observed 
over the first 24 hours after rinsing excess glyceraldehyde from the sclera (Figure 2.16).  
Ideally, a photoactivatable solution could be delivered to an area and then allowed to 
diffuse into tissue before activation.  Then upon activation, crosslinking would commence.  
After irradiation, no further modification would occur, giving the ability to precisely 
control the degree of crosslinking.  Second, traditional crosslinking is mediated by small 
molecules that spread quickly by diffusion—both into the intended tissue and surrounding 
tissues.  In the eye, there is the potential that crosslinking agents will be swept away in tears 
and in circulation, and there is a potential hazard that agents like GA will continue creating 
crosslinks as they move through the body.  This poses a danger in the eye where 
crosslinking in sensitive areas, such as the retina, should be avoided.  Photoactivated 
crosslinking can be localized to the intended area by selective irradiation. 
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While crosslinking with UV-A/Riboflavin does provide greater control than 
crosslinking with glyceraldehyde or other reducing sugars, the UV irradiation lasts 30 
minutes and has potential toxicity, especially when combined with photoinitiator 
activation.  Indeed, toxic effects on keratocytes have been observed during keratoconus 
treatment;7 and upon testing on rabbit sclera in vivo, “serious side-effects were found in the 
entire posterior globe with almost complete loss of the photoreceptors, the outer nuclear 
layer and the retinal pigment epithelium (RPE).”27 
Our present study examines alternative photoactivated systems that maintain the 
advantages of temporal and spatial control achieved with UV-A/riboflavin.  We examine 
several systems to test for photoactivated strengthening of tissue.  The results demonstrate a 
means to avoid the potential toxicity of UV light by using a visible light activated system of 
Eosin Y (EY) and triethanolamine (TEOA).  This visible light system combines a strong 
record of biocompatibility with crosslinking ability under irradiation doses that are 
clinically relevant (conforming to ANSI safety standards). 
3.2 Photoinitiator Systems 
Photoactivated systems rely on light and a photosensitizer—a molecule that is able to 
generate a radical through the absorption of light.  Such systems have been extensively 
developed for use in coatings and adhesives, and in tissue-engineering applications 
(Chapter 4).  The wavelength of light acceptable in the application guides the selection of 
the appropriate photosensitizer system.  In addition, water solubility, lipophilicity, and 
cytotoxicity are considered in biological systems. 
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During the course of this research, three photoinitiator systems have been used (Figure 
3.1): two UV photoactivated systems were used for proof of concept.  For convenience and 
solubility in water, preliminary experiments used (4-benzoylbenzyl)trimethylammonium 
bromide (Figure 3.1a).  The demonstration of oxygen inhibition of PEGDM polymerization 
within the tissue in Chapter 4 uses this initiator.  To avoid cytotoxicity, we next examined 
Irgacure 2959 (I2959, Figure 3.1b), which showed low toxicity over a range of mammalian 
cell lines relative to other UV-photoinitiators, including Irgacure 184, Irgacure 907, 
Irgacure 651, CQ/4-N,N-dimethylaminobenzoate, and CQ/Triethanolamine.28, 29  I2959 is 
used to demonstrate spatial control of photoactivated crosslinking in this chapter, and to 
demonstrate strengthening with and without creation of an integrated polymer network in 
the tissue.  Moving toward our goal of eliminating the potential cytotoxic effects of UV 
light, we devoted the greatest effort to an initiator system for use with visible light, EY with 
TEOA (Figure 3.1c), which has a well-established track record of biocompatibility in a 
range of applications (Table 3.1) and has gained FDA approval for use in the human body 
in the lung sealant FocalSeal® (Genzyme Biosurgical, Cambridge, MA).   
EY is a water-soluble xanthene dye and is a common stain for collagen, the main 
component of the cornea and sclera.  EY’s absorption peak at 514 nm allows efficient 
activation with visible light.  Upon irradiation, it becomes excited to the triplet state and 
undergoes electron transfer with TEOA, generating radicals.  The combined characteristics 
of low-toxicity light (green light) and low-toxicity initiator (EY/TEOA) were incorporated 
in the design of treatment protocols for the majority of in vitro, and all of the in vivo 
studies.  We use this system to illustrate temporal control of crosslinking in this chapter, to 
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demonstrate stabilization of eye shape using integrated polymer networks created in 
vivo in Chapter 4, and it is the system used for development toward a treatment of 
degenerative myopia (Chapter 5) and treatment of keratoconus (Chapter 6). 
 
  
 
Authors Application 
Nakayama et al.15 Hemostasis of Liver Tissue 
Orban et al16 Cardiovascular Applications 
Cruise et. al., Pathak et al., 
Desmangles et al.17-19 
Islet Cell Encapsulation / 
Microencapsulation 
Elisseeff et al.21 Transdermal Polymerization 
Luman et al. 
Carnahan et al.22, 23 
Close Linear Corneal Incisions, 
Secure Lasik flaps 
Alleyne et al.24 Dural Sealant in Canine Craniotomy 
(FocalSeal) 
West et al.25, 26 Thrombosis Inhibition 
Table 3.1.  Literature Demonstrating Biocompatibility of Eosin Y 
 
 
(4-Benzoylbenzyl)trimethylammonium Bromide 
 
Triethanolamine Eosin Y 
Figure 3.1.  A) (4-Benzoylbenzyl)trimethylammonium Bromide and B) Irgacure 2959 are 
UV activated photoinitiators, and C) Eosin Y/TEOA is a visible light activated system 
A) 
C) 
B) 
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3.3 Temporal and Spatial Control of Treatments 
The following in vitro experiments illustrate the ability to control the degree of crosslinking 
using the duration of irradiation, and to achieve spatial control of photoactivated 
treatments.  Collagen gels are used in lieu of cornea or sclera specimens to establish the 
relationship between irradiation time and extent of crosslinking.  Irradiation of porcine 
sclera through a mask is used to demonstrate spatially resolved activation. 
3.3.1 Temporal Control of Treatments 
Methods: We have built custom photorheology equipment that allows us to record changes 
in mechanical properties of specimens during irradiation.  Using this, we record the 
modulus of collagen gels with time before, during, and after irradiation. 
For these experiments, 8-mm-diameter circular sections of 1-mm-thick slabs of 20% 
gelatin with 0.0289 mM Eosin Y and 90 mM TEOA were mounted on the center of the 
shear rheometer (AR1000, TA Instruments) modified to allow measurement of light-
induced changes (Figure 3.2).  The sample was subjected to oscillatory shear with a stress 
amplitude of 30 Pa and frequency of 0.3 rad/sec, at which the initial storage modulus is 
approximately 3000 Pa.  The dynamic moduli were recorded every 48 seconds for 20 
minutes prior to irradiation, during 20 minutes of irradiation, and then monitored for 20 
minutes while in the dark (Figure 3.3).  Light emitting diodes (LEDs) at 525 ± 16 nm were 
used to give an irradiance at the sample of 1–3 mW/cm2. 
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Results: Control samples that receive no light (0 mW/cm2) do not show any increase in 
modulus throughout the experiment (Figure 3.3).  The change in modulus increases 
approximately linearly with time at each of the three flux levels examined (1, 2, and 3 
mW/cm2).  Further, the increase in modulus does not continue after cessation of irradiation.  
Therefore, the degree of crosslinking can be controlled using the duration of light exposure.  
Note that the modulus change may asymptotically approach a maximum rate, and 
increasing the light intensity beyond a certain value (~3 mW/cm2) will simply deposit 
excess energy in the system without increasing the rate.  Also note that 5 minutes of 
irradiation is used in the in vitro and in vivo experiments described in Chapters 5 & 6.  The 
storage modulus of the model gel increases approximately 5% after 5 minutes of irradiation 
with a flux in the saturated regime (3 mW/cm2).  Because the increase in modulus is 
controlled by factors (light intensity and exposure time) that can be easily controlled in the 
clinic, a treatment can be modified to suit an individual patient.  Also, the ability to deliver 
 
Figure 3.2.  Setup for measuring real-time 
changes in sample modulus while exciting 
with light on a shear rheometer 
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the drug to the proper location and then activate it with light will ensure that the proper 
area is treated. 
Photorheological monitoring of crosslinking in collagen gels takes advantage of relatively 
simple techniques that can be used to screen the effects of light intensity, wavelength, EY 
concentration, TEOA concentration, and the interactions of these parameters without the 
use of animals.  Future drug optimization experiments requiring animals can then be more 
intelligently designed based on these test results. 
 
3.3.2 Spatial Control of Treatments 
Because the photoinitiator system is only activated upon irradiation with light, it should be 
possible to selectively activate regions of interest within the tissue.  Clinically, this means 
that drug may be applied to a broad area, and then activated precisely where needed.  In 
Figure 3.3. The change in storage modulus G′ as a 
function of time prior to irradiation (t = 0–20 
minutes), during irradiation (t = 20–40 minutes), and 
in the dark after irradiation (t = 40–60 minutes) with 
525 nm LEDs at the flux indicated in the legend
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order to determine where treatments are activated, Dr. C.J. Yu synthesized a 
Fluorescein-PEG-methacrylate (Fluor-PEGM) molecule that is fluorescent and capable of 
coupling to tissue upon reaction with radicals generated by the photoinitiator (Figure 3.4a).  
A porcine eye was immersed in a treatment solution (Fluor-PEGM—fluorescent & 
Irgacure 2959—which does not have visible fluorescence) for 5 minutes, then the surface 
was wiped clean of excess material.  A mask was used during irradiation so that only 3 slits 
of light fell on the posterior sclera.  The eye was rinsed in DPBS for 48 hours to allow free 
Fluor-PEGM to diffuse out of the tissue, and then examined under a black light to visualize 
fluorescence.  Three fluorescent bands were evident (Figure 3.4b).  The location of the 
three fluorescent bands that persist on the sclera correspond to the irradiated regions, 
indicating activation of the photoinitiator and crosslinking of Fluor-PEGM (Figure 3.4b).  
The dark bands coincide with areas that did not receive light through the mask. 
Treatment of degenerative myopia will likely involve an injection behind the eye, where 
solution may diffuse into periorbital fat and neighboring muscles.  Activation of 
crosslinking only where light is directed (i.e., onto the sclera) will protect these other 
tissues.  Strengthening of cornea and sclera can also be directed selectively to areas of 
thinned or weakened tissue without crosslinking healthy areas.  Thus, the combined 
advantages of temporal and spatial control provided by photoinitiator systems increase the 
ability to tailor treatments to individual patients. 
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3.4 Light Safety and Clinical Relevance 
We hypothesized that visible-light irradiation would facilitate activation of photoinitiator 
systems using safe levels of irradiation within the cornea and sclera.  In view of the 
experimental results, we compare the irradiation dose that is used above (525 ± 16 nm 
LEDs, and 6–8 mW/cm2 at the plane of the tissue) and is used for eye stabilization in 
O OHO
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O
+
+
Fluorescein-PEG-NHS (Shearwater)
2-Aminoethyl methacrylate hydrochloride
Fluorescein-PEG-methacrylate
N-Hydroxysuccinimide
H2O 
Figure 3.4.  A) fluorescent molecule capable of binding to 
tissue after light-activated crosslinking (Fluorescein-PEG-
methacrylate) was prepared from a precursor fluorescein-
PEG-NHS (2000 dalton) and 2-aminoethyl methacrylate 
hydrochloride by reacting overnight in H2O in the dark.  
The reactive methacrylate group is capable of binding to 
tissue upon activation by radicals and B) the fluorescent 
molecule has been crosslinked to form three bright green 
bands on the posterior sclera of a porcine eye, 
demonstrating the ability to localize treatment. 
A) 
B) 
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Chapters 5 and 6 to existing standards for safe exposure.  The American National 
Standards Institute (ANSI) provides the American National Standard for Safe Use of 
Lasers30, and although we are using an LED light source instead of lasers, these standards 
provide a guideline for the safe irradiation of the eye.  Because of reduced photochemical 
hazards at longer wavelengths, the maximum permissible exposure (MPE) of the retina to 
green light (525 ± 16 nm) is approximately 30 times greater than the MPE for blue light 
(400 nm).  We use the MPE for blue light (2.7 J/cm2) to make a conservative estimate for 
irradiation safety.  The safety thresholds for clinical treatment of keratoconus are more 
stringent than those for degenerative myopia due to the potential exposure of the retina to 
the treatment irradiation. 
For keratoconus treatment, light directed onto the cornea is transmitted through the cornea, 
lens, and vitreous and to the retina with minimal loss.  Using the MPE for retinal irradiance 
(ER), we can calculate the maximum permissible source radiance (LS): 
2
24
P
R
S d
fEL ⋅⋅
⋅⋅= τπ , 
31 
where τ is the transmission through the ocular media (conservatively taken to be 100%), f is 
the focal length of the eye (1.7 cm), and dP is the diameter of the pupil (0.7 cm).  This gives 
LS of 20 J/(cm2sr).  Calculating the exposure at the cornea can be done using the geometry 
of the light source, which can be taken as 1 cm in diameter (DS) a distance 1 cm from the 
cornea (r).  The irradiance at the cornea is: 
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2
2
4 r
DLE SSC ⋅
⋅⋅= π = 15.7 J/cm2. 
For a 300 second exposure, this would correspond to a maximum permissible irradiation of 
52 mW/cm2, which is 6.5 times greater than the irradiation (8 mW/cm2) used in the in vitro 
keratoconus studies in Chapter 6. 
For treatment of degenerative myopia, light delivered from the outside of the eye must pass 
through the sclera and the choroid before reaching the retina.  To obtain conservative safety 
criteria, calculations here are based upon the minimum thickness and minimum absorption 
coefficients of the sclera and choroid, neglecting scattering in the sclera and choroid.  On 
this basis, less than 5 % of light incident on the sclera will irradiate the retina (Table 3.2).  
The MPE for retina remains the same as above (2.7 J/cm2).  Although ANSI does not 
provide an MPE value for the sclera, exposure of the skin to visible light of duration > 10 
seconds should not exceed 200 mW/cm2.  Based on these limits, the irradiation (6–8 
mW/cm2) used in studies on degenerative myopia (Chapter 5) with visible light falls well 
below the safety limits (by a factor of 25, Figure 3.5). 
Tissue Absorption Coefficient, μ (mm-1) 
Thickness, l 
(mm) 
Transmittance 
I/Iincident = e-μl 
Choroid 1532 0.2 0.05 
Sclera 0.39 (for 500 nm)33 0.3934 0.86 
Table 3.2 Calculation of Light Absorbed by the Choroid and Sclera 
 
Calculations yield margins of safety with factors of at least 6.5 and 25 for treatment of 
keratoconus and degenerative myopia, respectively.  The safety of this irradiation on rabbit 
and guinea pig sclera has been verified during in vivo biocompatibility studies (Chapter 5).   
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In relation to clinical application, considerations beyond safety may motivate further 
reduction of the irradiation dose.  The MPE values from ANSI are below known hazardous 
levels for creation of retinal lesions.  Thus, the calculations above indicate that the 
irradiation used should not damage any ocular tissues; it may still be uncomfortable to view 
or cause perturbed color perception for a period of time after treatment.  Further reduction 
in intensity may increase patient comfort.   
The key factors that led to the decision to use EY/TEOA for development of a clinically 
relevant treatment in Chapters 5 and 6 are: 1) efficacy with irradiation that is considered 
safe with respect to ANSI standards, 2) previously demonstrated biocompatibility of 
EY/TEOA, and 3)  temporal and spatial control (like other photoinitiator systems). 
 
Figure 3.5.  Safety calculations based on ANSI standards 
reveal that treatment using the current protocol of 525 ± 16 
nm at 6–8 mW/cm2 for 5 minutes directed onto the posterior 
sclera from outside the eye is well below the safety limits. 
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first year, who assisted with in vivo treatment of rabbit eyes.  Undergraduates Dennis Ko 
and Meredith Wiseman contributed to the study of fluorescent molecules within the sclera. 
4.1 Tissue Engineering 
Tissue engineering is an attractive approach for treating keratoconus and degenerative 
myopia because of the potential to replace or reinforce old, diseased, or malfunctioning 
tissue.  Hydrogel based materials are traditionally used in tissue engineering because of 
their adjustable mechanical and chemical properties, biocompatibility, and 
biodegradability.1  These characteristics have been employed in biosensor coatings, drug 
delivery devices, the encapsulation of cells, cell delivery to tissue, and the creation of 
biodegradable scaffolding for new tissue growth.2-4  Photopolymerizable hydrogels can be 
injected as a liquid and then solidified by exposure to light in a controlled, localized 
manner.5  This method has demonstrated usefulness in filling voids in bone,5-7 in wound 
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healing, and in creation of an engineered tissue, e.g., cartilage in a specified location 
and shape.4, 6-11 
Poly(ethylene glycol) (PEG) or PEG-based materials have been widely used in hydrogel 
and tissue engineering applications, and PEG-diacrylate has been approved by the FDA for 
use in the body.  PEG-based hydrogels formed by photopolymerization in the body have 
already shown clinical applicability in treatment of lung and dural tissues.12, 13  PEG-based 
macromers may have varying-length PEG chains, which alters the solubility of the 
macromers and, upon polymerization, can create different crosslink densities (or modulus) 
of the polymerized network.  By incorporating appropriate amino acid sequences along the 
PEG chains, the matrix can contain cell-binding domains, enzymatically degradable 
sections, growth factors, etc.  This allows for artificial direction of cell growth and 
behavior.  Also, PEG can be functionalized with varying end groups such as methacrylate, 
to give different reactivities.  Radical generation by the photoinitiator initiates reaction of 
the endgroups, which form bonds with other macromers and/or with the tissue.  Because of 
the customizability of PEG-based macromers, they have been chosen for use in our 
preliminary treatment mixtures. 
While literature on tissue engineering typically focuses on the filling of voids, surface 
modifications, and temporary support for growing tissue, an alternative approach that we 
have studied for the cornea and sclera is the creation of an integrated polymer network 
within the tissue.  By first allowing the tissue to imbibe photopolymerizable material, 
crosslinking incorporates the new material inside the tissue.  This interpenetrating network 
could increase structural support, and through covalent crosslinks, could lock pre-existing 
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structures in place and prevent tissue reconfiguration.  In the present case, it might 
prevent excessive deformation or tissue remodeling in keratoconus and degenerative 
myopia.  In addition, we have demonstrated that it can be used to anchor labels or other 
functional moieties into the tissue (illustrated in Chapter 3 using Fluorescein-PEG-
methacrylate).  In studies of the mechanical properties related to polymerization or grafting 
of PEG-dimethacrylate (PEGDM) into ocular tissues, we have examined 1) the 
concentration dependence of modulus increases in sclera, 2) the relationship of oxygen to 
the modulus increase in sclera, and 3) the stabilization of eye shape with and without an 
interpenetrating network. 
4.2 Concentration & Oxygen Dependence of Increases in Scleral Modulus 
The density of the new network (artificial and natural), or the degree of crosslinking is 
expected to determine the treated tissue modulus.  For example, a controlled increase in 
tissue modulus might be achieved by increasing the concentration of PEGDM, which is 
expected to increase crosslink formation. 
In addition to control of the final modulus, in the case of degenerative myopia, we desire 
selective polymerization within sclera and not within vessel walls that penetrate the 
posterior sclera (Figure 4.1a).  Oxygen inhibition of radical polymerization is commonly 
observed,14, 15 which could be an advantage in this situation.  Because sclera is largely 
avascular, we can exploit the differential concentration of oxygen within vessel walls 
compared to adjacent sclera to control polymerization.  In and around blood vessels where 
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oxygen tension is higher, polymerization will be inhibited; further away, in avascular 
portions of the sclera where the oxygen tension is lower, polymerization will occur. 
To test these hypotheses regarding the effects of concentration and oxygen on photo-
activated incorporation of PEGDM, we use oscillatory shear measurements of the 
mechanical properties of porcine sclera specimens before and after treatment. 
Methods: Eyes from 3–4 month old swine were obtained from Sierra for Medical Science.  
Tissue was shipped on ice, in saline to maintain proper hydration and freshness.  The fresh 
eyes (< 72 hours post mortem) were dissected to remove orbital fat and muscles, and then 
cut at the equator to separate the anterior and posterior globe.  The episclera, retina, and 
choroid were removed before cutting a circular disk from the posterior pole with an 8-mm-
diameter trephine punch.  The center of the circular section was located ~10 mm from the 
optic nerve on the temporal side.  The sections were immediately put on the rheometer for 
oscillatory shear tests at a frequency of 1 rad/sec and a stress amplitude of 5 Pa. 
After initial modulus measurements on the rheometer, tissue sections were soaked for 1 
hour in a solution containing a specific concentration (0, 1, 5, 10, or 25 % w/w) of PEGDM 
(550 Dalton) with 1% 4-benzoylbenzyl trimethylammonium bromide (Initiator A: Figure 
3.1a) in Dulbecco’s phosphate-buffered saline (DPBS).  After soaking for 1 hour, excess 
solution was removed from the tissue surface by dabbing with a kimwipe.  The samples 
were mounted in a humid chamber that allowed control of oxygen in the atmosphere 
(Figure 4.1b).  The atmosphere was either argon or air during irradiation.  After 5 minutes 
of equilibration in the chamber, a Thermo Oriel 500 Watt mercury xenon arc lamp was 
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used to irradiate with approximately 4 mW/cm2 365 nm UV light for 30 minutes.  
Following irradiation, the samples were rinsed for 4 hours in DPBS to remove unreacted 
macromer and initiator, and then modulus was measured again. 
The storage modulus of each specimen was measured prior to the treatment protocol and 
again afterward.  The same frequency and stress amplitude (1 rad/s, 5 Pa) were used for all 
measurements.  The frequency and stress amplitude were chosen from the range of values 
where the modulus was in the linear regime.  The temperature used for the soak and 
atmospheric chamber during irradiation was room temperature, and rheological 
measurements were done at 37ºC.  For each specimen, the “% change in G′” was evaluated 
as 100x(G′after-G′before)/G′before.  Four specimens were examined for each condition: the 
mean and standard deviation are shown by the symbols and vertical bars in Figure 4.1c. 
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Results: A statistically significant increase in modulus was observed with as little as 5% 
PEGDM added to the solution.  Increasing PEGDM concentration in the mixture generally 
increases the change in modulus of the sclera (Figure 4.1c).  The change in tissue modulus 
for irradiation in the presence of oxygen is significantly less than that for irradiation under 
argon.  At PEGDM concentrations of 25% w/w, the change in modulus while under argon 
was 240 ± 110 %, while in the presence of oxygen from air the modulus was 99 ± 65%.  
The modulus change in the presence of oxygen is less than half that achieved under argon 
for all concentrations of PEGDM 5% and above. 
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Figure 4.1.  A) Schematic illustration of the collagen network of the sclera, depicting 
oxygen-rich blood vessels that should be avoided during polymerization.  B) Humid 
chamber to provide UV light to tissue samples while maintaining proper hydration in 
different purge gases.  C) Change in storage modulus of porcine sclera tissue sections at a 
frequency of 1 rad/sec, and oscillatory shear stress amplitude of 5Pa as a function of the 
concentration of PEGDM (0–25% w/w in DPBS) used in the treatment solution (see 
text).  Samples received UV irradiation in either ambient O2 (air) or no O2 (argon).  Results 
indicate a concentration-dependent increase in modulus.  Presence of oxygen clearly 
decreases effectiveness of the reaction.  Each data point is an average of 4 samples. 
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Discussion:  The dose-dependent response of the tissue (increase in modulus with 
increasing %PEGDM) should enable the adjustment of individual treatments to achieve 
different desired end properties.  The changes that occurred for the ~ 2 hour treatment with 
25% w/w PEGDM under argon (240 ± 110 %) were comparable to those for a 24 hour 2% 
glyceraldehyde crosslinking treatment described in Chapter 2 (330 ± 110 %, Figure 2.16).  
Such shortening of treatment time would be beneficial for clinical application. 
The inability to crosslink efficiently in the presence of oxygen could be a beneficial for this 
system.  For the treatment of degenerative myopia it will be necessary to deliver drug 
around the back of the eye and close to the retina.  The ability of oxygen to inhibit the 
reaction could provide a method by which strengthening of tissue is done everywhere 
except in close proximity to oxygen-rich vessels.  This is especially relevant to prevention 
of crosslinking the short posterior ciliary arteries that penetrate sclera in the macular region 
and around the optic nerve.  If drug and light did reach the choroid, the oxygen-rich layer 
could prevent damaging crosslinking there as well. 
4.3 Crosslinking Without PEGDM 
In addition to controlling tissue modulus by altering the PEGDM concentration, adjusting 
the treatment protocols (initiator concentration and soak time) and irradiation parameters 
(wavelength, intensity, exposure time) can be used to control the reaction.  Shorter soak 
times prevent the drug from penetrating far into the tissue, and the light exposure controls 
the degree of activation.  By examining these parameters, we discovered strengthening of 
the tissue was possible without any macromer, as illustrated by the following experiments. 
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Methods: Eyes from 3–4 month old swine were obtained from Sierra for Medical 
Science.  Tissue was shipped on ice, in saline to maintain proper hydration and freshness.  
The fresh eyes (< 72 hours post mortem) were dissected to remove orbital fat and muscles.  
The whole eyes were soaked for 60 minutes in one of three solutions prepared in DPBS: a 
control of only DPBS, 0.3% I2959 in DPBS, or 20% PEGDM (550 MW) with 0.3% I2959 
(I2959, Figure 3.1b).  Afterward, sections of the eyes were irradiated with UV (~50 
mW/cm2, 315–405 nm, for 5 minutes) using a mask and then 8 mm disks were cut from 
irradiated and non-irradiated sections of the sclera.  The samples were soaked for 24 hours 
in DPBS and then measured for modulus using oscillatory shear measurements.  The 
difference in modulus between the exposed and unexposed regions was compared. 
Results: Specimens from control eyes soaked in DPBS showed little difference in modulus 
between exposed and unexposed regions (14 ± 33%).  The tissue sections from eyes 
receiving only initiator, or a combination of initiator and PEGDM both displayed increases 
in modulus in the exposed regions (290 ± 180%, and 150 ± 110% respectively).  Due to the 
large scatter, there is not a significant difference between the treatment with and without 
PEGDM (p > 0.05 as determined using an unpaired t-test) so it is not possible to 
conclusively determine which treatment was better. 
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Discussion:  These results indicate that treatments using only initiator and light have the 
capability of strengthening tissue by inducing crosslinking within the native components of 
the tissue.  While the use of PEGDM allows the incorporation of degradable polymer 
sections, growth factors, and the possibility to further control stiffness through altering 
molecular weight, the use of just an initiator would greatly simplify the treatment and 
reduce the number of variables that must be studied. 
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Figure 4.2.  Eyes soaked in treatment solutions of 
DPBS, 0.3% I2959, and a mixture of 0.3% I2959 
with 20% PEGDM were partially exposed to UV 
irradiation.  Modulus values from tissue sections of 
the exposed region, G′UV are compared to those of 
tissue sections from the unexposed region G′no UV 
to give a % difference of modulus due to 
treatment.  Treatment with I2959 and treatment 
with the PEGDM initiator mixture both cause 
increases in modulus.
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4.4 In Vivo Treatment Comparison With and Without PEGDM 
As discussed in the previous section, it is possible to increase tissue modulus with or 
without PEGDM present.  Although there are advantages to either approach, they appear to 
have similar effects on modulus and it is not clear which will provide the best treatment in 
vivo.  A set of experiments was conducted on rabbits in order to determine the efficacy of 
in vivo treatment with or without PEGDM while using the Eosin Y (EY) and 
triethanolamine (TEOA) photoinitiator system (Figure 3.1c).  This system was chosen 
based on issues of safety discussed in Chapter 3. 
Methods:  The detailed methods for in vivo treatment delivery and irradiation are given in 
Chapter 5.  For these experiments, 6 rabbits (12 eyes) received a subconjunctival injection 
of one of the following three solutions (Table 4.1): 1) control solution (DPBS), 2) 0.3 mM 
Eosin Y and 90 mM Triethanolamine in DPBS (10x EY), or 3) 10x EY with 10% PEGDM, 
550 MW (10x EY w/PEGDM).  After allowing 5 minutes for drug to diffuse into the 
sclera, the eyes were irradiated for 5 minutes using ~525 ± 16 nm, ~2 mW/cm2 light.  The 
animals were sacrificed on the same day that treatment was performed.  The eyes were 
enucleated and then tested using the intact globe expansion method (Chapter 2). 
Group # of eyes EY 
concentration 
TEOA 
concentration 
PEGDM 
concentration 
1) DPBS 4 None None None 
2) 10x EY 4 0.3 mM 90 mM None 
3) 10x EY w/PEGDM 4 0.3 mM 90 mM 10 % w/w 
Table 4.1 In Vivo Treatment Comparison with and without PEGDM 
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Results: Treatment with either 10x EY or 10x EY w/PEGDM reduces the expansion 
of the sclera as compared to controls (SP, ED, SL, Figure 4.3).  Because drug was only 
applied to the subconjunctival sclera, the corneas were untreated and changes in CP, CD, 
and CL are similar in treated and control eyes.  The reduction in expansion along CD is 
most likely due to treatment effects at the limbus which constrain expansion of sclera 
around the edge of the cornea.  Treatment without PEGDM may be slightly more effective 
at preventing expansion of the eyes, with average values of SP, ED, and SL being lower 
than those from treatment with PEGDM. 
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Figure 4.3.  Rabbit eyes were treated in vivo and then examined using the intact globe 
method ex vivo in order to compare the treatment effects with and without macromer 
(PEGDM).  Changes to scleral dimensions SP, ED, and SL are similar for both 
treatments, and there is some decrease in expansion along CD.  Only the sclera was 
treated, so SP, ED, and SL are expected to differ from controls, while CP, CD, and CL 
may show minor changes.  The measured ocular dimensions are illustrated in the side 
figure. 
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Summary: Previous work involving interpenetrating networks and tissue has 
demonstrated the use of these systems for ensuring hydrogel-to-tissue adhesion.  West and 
coworkers have reported interfacial photopolymerization of PEGDM networks and tissue 
where the liquid form of the hydrogel penetrates into crevices in the tissue surface and 
upon polymerization, enhances adhesion between the final hydrogel coating and the 
tissue.16, 17  In contrast to their work, we have demonstrated that interpenetrating networks 
can be used to increase the strength of tissue.  The use of interpenetrating networks to 
control increases in the modulus of the cornea or sclera could be excellent treatments for 
keratoconus and degenerative myopia, particularly because of the potential to functionalize 
the network.  Preliminary studies by undergraduate students Meredith Wiseman and Dennis 
Ko have shown the ability to deliver fluorescein-PEGM molecules within the sclera and 
immobilize them at a depth within the tissue (Figure 3.4), demonstrating functionalization 
and crosslinking of molecules inside the tissue. 
Confocal microscopy of sclera from eyes soaked in the crosslinkable fluorescent molecule 
for 10 minutes reveals a gradient in fluorescence that varies with depth (Figure 4.4).  The 
gradient in crosslinking is due to a concentration gradient from diffusion of molecules into 
the tissue, and due to light attenuation by the tissue.  Future work that varies the 
crosslinking profile may illustrate differences in the mechanical properties (i.e., when 
PEGDM is present throughout the depth of the tissue instead of just the surface).  Changing 
the soaking time, the time between soaking and irradiation, and the wavelength of light 
used for activation could all be used to modify the crosslinking. 
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Results from this chapter indicate that the tissue can be strengthened by crosslinking of the 
native components of the tissue without the use of photopolymerizable molecules.  Future 
studies could reveal certain conditions at which PEGDM plays the dominant role in 
strengthening the tissue, or other conditions at which crosslinking of the native tissue 
components dominates the strengthening.  Studies on model systems using simple amino 
acids could reveal the interactions that are most important in the mechanism of crosslinking 
for both native tissue and interpenetrating networks. 
The simplicity of using a photoinitiator-only system as the treatment is attractive because it 
can reduce the steps toward clinical use.  In Chapters 5 and 6, we will focus discussion 
primarily on the use of EY/TEOA for treatment of degenerative myopia and keratoconus 
respectively.  
 
Figure 4.4.  A) The confocal fluorescence image of porcine sclera shows fluorescence 
intensity of crosslinked fluorescein-PEGM within the tissue after a 10 minute soak, and B) 
a profile of the intensity as a function of depth demonstrates the gradient crosslinking 
within the tissue. 
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5.1 Introduction 
In degenerative myopia, the reduction of collagen fibril diameter, enhanced turnover of 
scleral collagen, and alteration of scleral glycosaminoglycans results in mechanical changes 
to the sclera.1  Progressive elongation of the eye in degenerative myopia is thought to be 
the result of 1) the tissue being inherently weak, 2) the sclera continuously being 
remodeled, or 3) a combination of these.1, 2  From studies of human donor tissue, high 
myopia is associated with weakening and thinning of the sclera, a reduction in matrix 
material, and reduction in collagen fibril diameter.  While refractive errors induced by 
progressive myopia are readily corrected by spectacles, contact lenses, corneal refractive 
surgery, or intraocular lenses, these modalities do not prevent visual loss induced by 
stretching of chorioretinal tissues.  Current means to treat choroidal neovascularization in 
degenerative myopia, such as photodynamic therapy, are minimally effective,3 and studies 
have only recently begun to test injections of anti-angiogenic drugs such as bevacizumab 
(Avastin®), or Lucentis®.4-8  Various attempts have been made to treat expansion of the 
eye due to myopia, including the use of scleroplasty, scleral reinforcement, and even an 
attempt to polymerize foam around the eye.9-18  Largely because these modalities remain 
unproven in well-controlled clinical trials, none have been widely adopted to manage 
patients with degenerative myopia. Current therapies are essentially palliative, attempting 
to mitigate visual loss in this condition. 
Crosslinking of scleral components has the potential to halt progression of degenerative 
myopia because it addresses both of the underlying causes that are currently hypothesized: 
crosslinking increases tissue strength and hinders tissue remodeling.19-21  As mentioned in 
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Chapters 1 and 3, Wollensak and Spoerl have reported the use of collagen cross-linking 
agents, including glutaraldehyde, glyceraldehyde, and riboflavin-UVA treatment, to 
strengthen both human and porcine sclera in vitro.22  Glutaraldehyde and glyceraldehyde 
would be difficult to spatially control, and unwanted crosslinking of collagen in vascular 
and neural structures might have particularly untoward effects.  Use of light-activated 
riboflavin would seem preferable in this regard; however, when testing on a rabbit model, 
“serious side-effects were found in the entire posterior globe with almost complete loss of 
the photoreceptors, the outer nuclear layer and the retinal pigment epithelium (RPE).”23  
While crosslinking near the posterior pole would increase scleral modulus and potentially 
arrest myopic progression, there remains a need for a non-toxic crosslinking agent that 
could be activated using short exposure to a less-toxic light source.  Our research in 
Chapters 3 and 4 indicates that the visible-light-activated co-initiator system of Eosin Y 
(EY) and triethanolamine (TEOA) has the potential to fill this need. 
For transition of this treatment from the lab to clinical practice, biocompatibility and 
efficacy must be proven in an animal model of myopia.  Current state-of-the-art animal 
models to study the etiology of myopia rely on 1) visual form deprivation and 2) the eye’s 
tendency to correct refractive errors toward emmetropia.24  During development, eyes tend 
to grow excessively upon removal of spatial vision.  Form-deprivation models use this 
response to induce myopia either by placing semitransparent occluders over the eye, or by 
suturing the eyelid shut.25  The second animal model makes use of emmetropization of the 
eye, which is the process by which eyes change to focus images on the retina.  When minus 
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or plus lenses are placed over the eye, the eye adjusts its growth to bring the image into 
focus. 
As is observed in the human disease, form-deprivation animal models (e.g., tree shrew eyes 
covered with occluders for 12 days) also exhibit weakened sclearl tissue (e.g., increased 
scleral creep rates).  In these animal models, there is also a measurable change in the 
amount and type of collagen and proteoglycan present in the tissue, indicating abnormal 
remodeling of the sclera.  Sustained form-deprivation in animals induces changes in 
collagen fibril diameter and spacing analogous to the distinctive structure observed in 
human donor tissue of high myopes. 
Various animal models exhibit similarities to humans and each other.  Eutherian mammals, 
such as humans, monkeys, tree shrews and guinea pigs, share the trait that “the entire sclera 
consists of the fibrous, type I collagen-dominated extracellular matrix”.2  This feature sets 
them apart from other vertebrates, which have an inner layer of cartilage (e.g., in chicks).  
Indeed, the mechanism of emmetropization during form-deprivation in eutherian mammals 
(remodeling of the fibrous sclera) is different from that in other vertebrates (growth of the 
inner cartilaginous region).  Therefore, eutherian mammals provide a better model for 
testing treatments related to scleral remodeling for potential application in humans.  In light 
of the fact that tree shrews and monkeys are difficult to obtain and monkeys suffer from 
high variability of the results, researchers have been establishing other mammalian models.  
Guinea pigs have recently gained acceptance due to the fact that they rapidly develop 
myopia, the changes are large and reproducible, and they are easy to care for.26-32  This 
animal provides a model that is well suited for research requiring significant numbers of 
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animals, and at the same time demonstrates physiological and anatomical similarities to 
humans. 
Despite the fact that the mechanism of degenerative myopia in humans is not completely 
understood, the animal models of myopia do express the weakened sclera and excessive 
remodeling typical of the disease.  As will be demonstrated in this chapter, light activation 
of Eosin Y/TEOA strengthens the sclera; and as discussed in Chapter 3, non-enzymatic 
collagen crosslinking is known to decrease enzymatic degradation.  Therefore, treatment 
with Eosin Y/TEOA has the potential to address both putative mechanisms of degenerative 
myopia. 
This chapter illustrates efficacy and biocompatibility of this potential treatment.  
Stabilization of ocular shape is demonstrated for in vitro and in vivo drug delivery to rabbit 
eyes followed by in vitro eye expansion using the intact globe method (Chapter 2).  
Preliminary safety studies in rabbits suggested no ill effect of the treatment.  We have also 
conducted experiments to establish drug and light delivery protocols in guinea pigs and to 
assess the effect of EY/TEOA on ocular growth and form-deprivation myopia in 
collaboration with Sally McFadden at the University of Newcastle in Australia.  The 
current results indicate that EY/TEOA has an ability to alter ocular parameters of guinea 
pig eyes without altering gross ocular function or animal behavior. 
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5.2 Materials and Methods 
5.2.1 In vitro Treatment & In Vitro Expansion 
The following procedures were used for testing the effect of in vitro treatment of eyes on 
preventing expansion of intact rabbit kit globes subjected to an elevated intraocular 
pressure. 
Tissue Preparation: Eyes from 2–3 week old New Zealand White Rabbits (University of 
California at San Francisco) were stored in saline on ice for use within 48 hours of 
enucleation.  Immediately before testing, the extraocular muscles, the conjunctiva, and the 
episcleral tissues around the eyes were carefully removed to expose the sclera. 
Materials: Treatment solutions of 0.0289 mM EY and 90 mM TEOA in DPBS (henceforth 
called 1x EY) were prepared fresh.  As discussed in Chapter 3, these solutions are activated 
by visible light and have peak absorption at 514 nm.  The measured pH was 7.5 for the 
solution.  Glyceraldehyde (GA) solution was prepared by mixing 2% by weight DL-
Glyceraldehyde (Sigma) in distilled water.  The pH was adjusted to ~7.5 with HCl and 
NaOH. 
Eosin Procedure: Eyes were soaked for 5 min in 5 mL of treatment (1x EY) or control 
(DPBS) solution.  The eyes were removed from the soak and excess solution was wiped 
from the surface using a Kimwipe.  The treatment was activated by placing the eyes under 
one of two light sources: a high intensity mercury arc lamp equipped with a 450–550 nm 
bandpass filter that provided 34 mW/cm2, or a panel of seven light emitting diodes (LEDs) 
with a spectral output at 525 ± 16 nm that provided an irradiance of 7–10 mW/cm2, as 
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measured at the center position of the eye (Figure 5.1).  With the arc lamp, the anterior 
hemisphere of the eye was exposed for 5 minutes and then the eye was flipped and the 
posterior globe was exposed for 5 minutes.  With the LEDs, the entire eye was irradiated at 
once for 5 minutes.  The eyes were placed in a rinse solution of DPBS for 30–45 min and 
then loaded on the expansion setup which has been described in detail previously (Chapter 
2). 
 
Glyceraldehyde Procedure: Because of its well-documented effects as a crosslinker, a 
comparison group was treated with 2% GA solution.  To allow GA to penetrate into the 
cornea (for comparison to keratoconus treatments in Chapter 6), the corneal epithelium of 
enucleated eyes was removed by scraping with a scalpel blade.  The eye was then soaked in 
5 mL of 2% GA for 12 hours; when it was removed from the soak, excess solution was 
removed with a Kim Wipe.  The eyes were rinsed in a 20 mL bath of DPBS for ~5 seconds, 
 
Figure 5.1.  A) Schematic of the mercury arc lamp source where light of 
450–550 nm passes through a bandpass filter and is collimated onto the 
eye, which sits on moist gauze.  B) Close-packed arrays of 7 LEDs 
located 2.35 cm above and below the eye direct light onto the eye while 
it sits in a 1 cm circular hole in the Plexiglas holder. 
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and then put in a fresh 40 mL DPBS bath to rinse for 10 hours.  The eyes were then 
loaded on the expansion setup. 
As described in Chapter 2, the expansion protocol began with a 1 hour interval at an 
intraocular pressure (22 mmHg) close to the physiologic value, which allowed the globe to 
recover from shape distortion that may have occurred during handling post mortem.  Then 
the pressure was raised and held at 85 mmHg for 24 hours.  Digital photographs (2272 x 
1704) were acquired every 15 min for the duration of the experiment. 
5.2.2 Biocompatibility 
Toxicity studies were performed at UCSF, to determine if the formulation and light 
exposure selected from in vitro studies would be suitable to use in an animal model for 
myopia.  To test the in vivo response to 1x EY and light exposure, the following 
experiments were performed using topical application of the drug. 
Procedure: Four adult New Zealand White rabbits were given general anesthesia with 1–
5% inhaled isofluorane administered by mask and topical 0.5% proparacaine to the right 
eye (OD).  The right eye of each animal was sterilized with 5% povidone-iodine 
(betadyne).  Throughout the procedure the eye was washed with sterile ocular balanced 
saline solution (BSS).  A 15 mm incision was made in the conjunctiva close to the limbus 
and another incision running anterior to posterior allowed the conjunctiva to be pulled 
away to expose the sclera over approximately 1 cm2 area.  The animal was positioned such 
that the exposed sclera faced upward and a drop of solution placed on it could remain in 
contact with the tissue for 5 minutes.  Rabbits from Group 1 had 200 microliters of 1x EY 
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solution applied directly to the exposed sclera.  Rabbits from Group 2 had 200 
microliters of DPBS (control) applied directly to the exposed sclera. 
After 5 minutes, the treated area was rinsed with 1–2 mL of BSS and then photoactivated 
by exposure to light from an LW Scientific Alpha 1501 Fiber Light Source (~34 mW/cm2) 
for 5 minutes. 
The conjunctival incision was closed with 7-0 vicryl suture.  All animals received 
subconjunctival injections of celestone (75–150 microliters) and cepahzolin (75–150 
microliters).  All animals were given injections of carprofen (5 mg/kg) and buprenorphine 
(0.05 mg/kg) for pain and 2–3 drops of neomycin, polymixin B sulfates, and gramicidin 
OD to prevent infection. 
Eyes were examined for any signs of pain or inflammation such as redness of the eye, 
discharge, ptosis of the eyelid, blepharospasm, or photophobia once a day for 1 week then 
once a week for 3 additional weeks. 
Histology: After 4 weeks all animals were anesthetized with 30–50 mg/kg ketamine and 5–
10 mg/kg xylazine, euthanized, and the eyes were removed, fixed in 10% formalin, and 
processed for light microscopic examination (Eosin/hematoxylin stain). 
5.2.3 In vivo Treatment & In Vitro Expansion 
The following experiments used in vivo treatment of the eye followed by in vitro expansion 
on the intact globe setup to test the ability to deliver drug and treatment in a live animal. 
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Materials: Although in vivo treatment does not permit soaking of an entire eye and 
direct access to the sclera is blocked by conjunctiva and tenon, subconjunctival/subtenon 
injection is a low-impact surgical procedure that permits drug delivery into the space 
adjacent to the sclera.  Literature on the subconjunctival delivery of mitomycin-C to the 
sclera indicates that only ~5% of drug present on the surface of sponges is able to diffuse 
into the sclera, and there is a preferential uptake by the conjunctiva.33-36  For this reason, a 
higher drug concentration than that used in vitro was used to achieve the desired dose in the 
sclera.  Literature reports excellent cell viability with Eosin Y concentrations up to 20 mM 
and TEOA concentrations up to 450 mM.37  Our in vivo studies used a solution with 0.289 
mM Eosin Y concentration, and 90 mM TEOA concentration, denoted 10x EY from here 
on.  Solutions denoted 10x EY w/PEGDM were a mixture of 10x EY with 10% w/w 
Poly(ethylene glycol) dimethacrylate.  All solutions were adjusted to pH 7.5 and passed 
through a 0.2 micron filter before use. 
Surgical Procedure: The procedures for in vivo drug delivery were conducted at UCSF and 
were performed on 2–3 week old New Zealand White rabbits.  The rabbits were given 
general anesthesia with 1–5% inhaled isofluorane administered by mask and topical 0.5% 
proparacaine to the eye.  The eye of each animal was sterilized with 5% betadyne.  
Throughout the procedure the eye was washed with sterile ocular balanced saline solution 
(BSS). 
A minimal procedure using subconjunctival injection (0.6–1.2 mL) placed the drug 
formulation in contact with the sclera.  Eight treated eyes were injected with 10x EY, four 
treated eyes were injected with 10x EY w/PEGDM, and four control eyes received an 
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injection of DPBS (Table 5.1).  The injection formed a pocket of fluid between the 
conjunctiva and sclera which remained during the 5 minutes given for diffusion (Figure 
5.2a).  During this time, the lids were closed over the eye.  After the 5 minute diffusion 
time, the lids were retracted and the eye slightly prolapsed.  A circular array of 525 nm 
LEDs was held around the eye for 5 minutes (Figure 5.2b).  The control eyes received 
irradiation of 2 mW/cm2, four 10x EY treated eyes received 2 mW/cm2, four 10x EY 
w/PEGDM treated eyes received 2 mW/cm2, and the remaining four 10x EY treated eyes 
received 6 mW/cm2.  After irradiation, the animals were sacrificed, and the eyes were 
enucleated and stored in DPBS on ice until use on the intact globe expansion setup at 
Caltech. 
 
In Vivo Rabbit Drug Delivery 
Set Light Protocol Drug Formulation # of Rabbits 
A 2 mW/cm2 DPBS 4 
B 2 mW/cm2 10x EY 4 
C 2 mW/cm2 10x EY w/PEGDM 4 
D 6 mW/cm2 10x EY 4 
Table 5.1.  Variations for In Vivo Rabbit Treatments and Ex Vivo 
Expansion 
 
Figure 5.2.  A) Schematic 
diagram of the observed fluid 
pocket around the eye created 
by subconjunctival injection 
A) B) 
of Eosin Y/TEOA formulations and  B) a flexible LED 
source which is held around the eye during 
circumferential irradiation
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Expansion Testing: Expansion experiments were performed within 48 hours post 
mortem.  The appearance of the eyes (e.g., clarity of the cornea and size of the globe) was 
unchanged over this time scale.  For the expansion experiment, extraocular tissues were 
carefully removed from the eye and then the eye was placed into DPBS for ~1 hour to 
equilibrate to room temperature.  The eyes were loaded onto the expansion setup where the 
intraocular pressure was set to 22 mmHg for 1 hour then increased to 85 mmHg for 24 
hours (Chapter 2 for details). 
5.2.4 Animal Model of Myopia 
These experiments in a guinea pig model were conducted in collaboration with Dr. Sally 
McFadden at the University of Newcastle, NSW Australia.  These tests examine the 
feasibility and safety of surgery, the safety of drug and irradiation, the effect of treatment 
on development of form deprivation, and the effect of treatment on normal ocular growth. 
Materials: All treatment solutions were prepared at pH 7.5 and passed through a 0.2 micron 
filter to ensure sterility for surgery.  The tests used DPBS, 3x EY (0.1 mM EY & 90 mM 
TEOA in DPBS), and 10x EY. 
Pigmented guinea pigs (Cavia porcellus, n = 47) were maternally reared and housed in 
their natural litters with their mothers in opaque plastic boxes (65 x 45 x 20 cm) with wire 
mesh lids.  Water (supplemented with Vitamin C), guinea pig food pellets, and hay were 
available ad libitum.  Light hoods containing incandescent bulbs evenly diffused through a 
perpex barrier were suspended 30 cm above each box and switched on a 12 h light/12 h 
dark cycle.  All procedures were approved by The University of Newcastle in accordance 
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with New South Wales Animal Research Act and were in accordance with National 
Institutes of Health Guidelines. 
Procedures: Animals were anesthetized with Ketamine (50 mg/kg) and Xylazine (5 mg/kg) 
and if necessary, administered a small dose of Bupremorphine (0.1 mg/kg).  The eyes 
received topical anesthetic as needed.  On the right eye, drug was delivered through 
subconjunctival injection (Figure 5.3), which was previously demonstrated as a successful 
method in rabbits.  Some animals received a sham surgery with injection of DPBS instead 
of drug (Table 5.2).  After subconjunctival injection, 10 minutes was allowed for diffusion 
of drug formulation into the sclera. 
   
In Vivo Guinea Pig Drug Delivery 
Set Light Protocol Drug 
formulation 
Form 
Deprivation
# of 
Guinea 
Pigs 
Day of Enucleation 
A No Irradiation 10x EY No 3 Immediate 
B No Irradiation No Treatment Yes 7 
C 3 Trisections 3x EY Yes 14 
D 3 Trisections 10x EY No 7 
17 days post surgery 
E Circumferential 10x EY No 8 
F Circumferential DPBS (sham) No 8 
30 days post surgery 
Table 5.2. Treatment Variations for In Vivo Guinea Pig Studies 
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After the 10 minute diffusion time, the right eyes of Sets C-E were prolapsed and irradiated 
in two different manners.  One group of animals had a superficial suture placed at the 
limbus for traction while prolapsing the eye (Sets C, D).  The eye was irradiated with an 
LED light source for 5 minutes at each of 3 trisections (Figure 5.4a).  The second group of 
animals had a piece of elastic placed around the eye to hold it prolapsed (Set E, Figure 
5.4b).  While prolapsed in this manner, a circular array of LEDs was placed around the eye 
for 5 minutes (Figure 5.4c, d).  We built the light sources from 525 ± 16 nm LEDs to 
provide 6–8 mW/cm2 at the plane of the sclera; the light for trisection illumination 
consisted of three 5 mm LEDs aligned to irradiate a 120 degree section of the eye while 
held a distance of ~8 mm from the eye, and the light for circumferential illumination 
consisted of 2 rows of twelve 3 mm LEDs ~2 mm from the scleral surface that could 
irradiate 360 degrees of the eye. 
Figure 5.3.  Controlled subconjunctival 
injection of 10x EY delivers treatment to 
the eye.  10x EY is seen as pink on the 
right side, and locations where 10x EY has 
not yet been delivered are seen as grey on 
the left side. 
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After irradiation, the eyes were placed back in the normal position and washed with 
antibiotic eyedrops.  The animals were placed back with their mothers after surgery and 
monitored to observe behavioral responses. 
Animals from Set A were immediately euthanized and the eyes were enucleated.  The eyes 
were examined for the presence of Eosin Y in the sclera. 
 
Elastic holding eye in 
prolapsed position 
C D 
B A 
Figure 5.4.  A)  Group 1—Irradiation of one trisection of a prolapsed guinea pig eye while 
a suture is used to control the exposed region.  B) Group 2—Elastic placed around the eye 
of an anesthetized guinea pig to hold the eye prolapsed during irradiation.  C)  The light 
source is place around the eye for 5 minutes, while D) LEDs provide circumferential 
irradiation. 
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The animals from Sets B and C included form-deprivation studies.  Diffusers were 
secured with velcro over the right eye when the animals were ~6 days old and the fellow 
eye was left untreated (Figure 5.5).  This was 2–3 days after surgery of animals in Set C.  
The animals were exposed to a 12h/12h light/dark cycle, and the diffusers were removed 
for 50–90% of the dark periods overnight.  Diffusers were also removed during 
measurements. 
 
Animals from Sets D, E, & F did not receive diffusers and they were monitored to observe 
normal growth of the eye. 
Measurements were made before surgery, and then periodically after surgery to track 
changes in eye shape throughout form deprivation and normal growth.  Corneal power was 
measured using IR videokeratometry.  The animals were cyclopleged (i.e., dilated) with 2 
drops of 1% cyclopentolate, and refractive error was measured using streak retinoscopy.  
Finally, the animals were anesthetized with 2% isoflurane in oxygen and the axial ocular 
parameters were measured using high-frequency ultrasound (20 MHz). 
Figure 5.5.  Method of attaching a diffuser in 
the guinea pig.  (A) Position of the Velcro 
arcs.  Dotted lines indicate the horizontal and 
vertical meridians used in retinoscopy.  (B) 
The diffuser held in place by a matching 
Velcro ring attached to its base (Howlett 
2006) 
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Within 2 days of the last ocular measurements, guinea pigs were euthanized and the 
eyes were prepared for histology.  A strip of tissue was dissected from the eye cup, fixed 
overnight in 4% glutaldehyde, imbedded in resin, cut in 1 μm sections, and then mounted 
and stained. 
5.3 Results 
5.3.1 In Vitro Application and In Vitro Expansion 
Treatment with GA was performed as a positive control to demonstrate the ability of 
crosslinking to prevent creep and the results have previously been discussed in Chapter 2.  
Motivated by the advantages of using a visible light activated crosslinking system, we 
chose EY/TEOA for these studies.  Digitized images from the expansion studies were 
analyzed to measure the ocular dimensions labeled in Figure 5.6.  Over the 24 hour period, 
control eyes expand continuously along every dimension (Figure 5.7).  This is expected due 
to the high pressure which induces creep.  The treated eyes resist expansion along SP, ED, 
and SL—dimensions associated with the sclera.  Expansion along dimensions associated 
with the cornea (CP, CD, and CL) increase in the same manner for treated and control eyes.  
Because the corneal epithelium remained intact during treatment, it provided a protective 
layer that prevented treatment of the cornea.  Removal of this layer in order to treat the 
cornea will be discussed in Chapter 6.  Because we are currently interested in the 
treatment’s ability to strengthen sclera for degenerative myopia, we will focus on results of 
SP, ED, and SL expansion (all components of the sclera). 
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Treatments tested with a high-intensity, broadband arc lamp source, and with a low-
intensity LED light source both show similar results after 24 hours (Figure 5.8).  Further 
reduction in the intensity may be possible using a light source more in tune with the 
absorption peak of EY (514 nm).  The use of low light doses (5 minutes, 6 mW/cm2) of 
visible wavelength may avoid the cytotoxic effects on the retina that were seen with larger 
doses of UV (30 minutes, 3 mW/cm2) used by Wollensak. 
 
 
Figure 5.6.  Measurement 
of Ocular Dimensions
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Figure 5.7.  Rabbit eyes subjected to a low prestress similar to normal intraocular pressure 
(22 mmHg) followed by a high (85 mmHg) pressure for 24 hours show the ability of eyes 
treated with 1x EY to resist creep.  The sclera of treated eyes remains stable (top row) 
while the cornea expands indistinguishably from control cornea (middle row).  For values 
of the overall dimensions, refer to Table 2.2. 
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5.3.2 Biocompatibility 
Biocompatibility studies were performed on albino rabbit eyes because the lack of 
pigmentation in these eyes allows for easy visualization of toxic or inflammatory 
responses.  In all of the eyes we operated on, there was some observed swelling and 
inflammation for 2 days following the procedure.  This was consistent with what would be 
expected to result from the surgical procedure itself.  There were no clinical signs of pain or 
inflammation in any of the eyes 3 days after the procedure and on each examination 
thereafter. 
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 Figure 5.8.  In vitro treatment: percentage 
change in scleral dimensions after 24 hour 
expansion—Eyes treated with 1x EY mixture 
and irradiation show reduced expansion in the 
intact globe experiment along SP, ED, and SL 
(Figure 5) as compared to controls treated with 
DPBS.  Similar efficacy is achieved using 
narrow-band LEDs (525±16 nm) at a low light 
dose as with a broadband arc lamp (500±50 nm) 
at a high light dose.  *significant difference from 
control with p < 0.05 
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Histological examination revealed that there was mild inflammation and scarring 
along the conjunctival-sclera junction in the surgical area of all the eyes.  The irises, 
retinas, and ciliary bodies were all normal in all experimental groups.  There was no 
significant difference in the sclera of treated (Figure 5.9a) and control eyes (Figure 5.9c), 
indicating that the mild inflammation and scarring which occurs is a result of the surgery 
and not of the treatment.  Likewise, the viability of cells in the nearby tissues of the treated 
eyes matches that of normal eyes.  
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Figure 5.9.  Histopathological examination of 1x EY Treatment (Group 1—a, b) and 
DPBS control vehicle (Group 2—c, d) treated rabbit eyes.  The arrows mark the boundary 
between the sclera and conjunctiva (sclera is to the left of the arrow).  All micrographs 
used 20x magnification.  The treated, irradiated area of Group 1 and Group 2 rabbits 
shows mild inflammation and moderate scarring (darker blue line of staining by the arrow) 
where the conjunctiva was retracted.  For comparison, the untreated, non-irradiated area 
of a Group 1 and Group 2 rabbits where conjunctiva was not retracted shows normal 
sclera and conjunctiva with no inflammation or scarring.  (Greater thickness of the sclera 
relative to (a) and (c) is characteristic of the location of the section.)  
Treated Area Non-Treated Area 
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5.3.3 In Vivo Application and In Vitro Expansion 
Average values of changes along ocular dimensions indicate that all injections except the 
control decrease the expansion of the sclera (Figure 5.10).  Values for expansion along SP 
and ED are significantly smaller compared to controls for the low-intensity treatment, 
while all values for the high-intensity treatment are significantly smaller than controls.  
Significance with p < 0.05 was determined by comparing values from treatment and control 
groups using an unpaired t-test.  After 24 hours of elevated pressure, in vivo treated eyes 
have an ocular stability comparable to that of the in vitro treated eyes (Figure 5.8).  This 
proves that the subconjunctival injection delivers drug to the sclera, and the 5 minute 
diffusion time is sufficient for 10x EY to penetrate into the live sclera.  In addition, the 
circumferential irradiation with LEDs is able to activate the treatment around the eye. 
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5.3.4 Animal Model of Myopia 
Using a guinea pig model, data was obtained regarding drug delivery, toxicity, and 
tolerance of surgical procedures.  After surgery, there was minimal inflammation of the 
conjunctiva that disappeared within 2–3 days.  The eyes had a normal pupil response and 
clear ocular media which allowed for streak retinoscopy measurements.  Gross ocular 
function (pupillary reflexes, response to light, blink reflex) appeared normal.  Behaviorally, 
the animals moved about the habitat normally and had normal eating and drinking habits. 
Observations of the sham surgery controls indicated that the surgical procedure was well-
tolerated by the eyes.  The eyes receiving the 3x EY and 10x EY formulations 
demonstrated no evidence of toxicity problems.  Tissue sections from treated and fellow 
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Figure 5.10.  In vivo treatment after 24 hour 
expansion—Eyes treated with 10x EY and 
irradiation show reduced expansion in the intact 
globe experiment as compared to controls 
treated with DPBS and irradiation.  Treatment 
with 6 mW/cm2 may have greater stabilizing 
effects than with 2 mW/cm2.  Control and 
treated groups show similar behavior as in vitro 
treated eyes (Figure 5.8). 
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eyes showed that the sclera was structurally normal (Figure 5.11).  The sclera, choroid 
and retinal pigment epithelium (RPE) had no signs of toxicity from the treatment.  There 
were normal RPE cells and depigmented RPE cells in the treated and untreated eye 
sections.  The sclera of treated and untreated eyes is indistinguishable.  Although the retina 
was removed before fixing the tissue, the overall retinal thickness was within the normal 
limits and no signs of retinal toxicity were observed.  These important findings support our 
hypothesis that the treatment is safe based on EY/TEOA literature,1-11 light- and drug-
penetration calculations, and rabbit histology. 
 
Of the three eyes enucleated immediately after treatment (Set A), all showed pink staining 
from Eosin Y over the entire sclera, including at the posterior pole, indicating that the 
formulation can be delivered to the entire sclera following subconjunctival injection. 
Figure 5.11.  Histological sections from 10x EY treated guinea pig eyes and untreated 
fellow eyes show the sclera but the retina was detached before fixing.  There are 
depigmented RPE cells in both the treated and untreated eyes.  There are normal RPE 
cells present in the treated eye.  (*) The choroid is detached from the sclera in the treated 
eye due to artifacts of the sample preparation.  The sclera appears the same in the treated 
and untreated eye. 
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Results of normal form-deprivation with untreated eyes (Set B) are presented along with 
results for form-deprivation of 3x EY treated eyes (Set C).  Measurements of refractive 
state before surgery indicate that the guinea pigs are hyperopic, which is expected for their 
age (Figure 5.12).  Immediately before beginning form-deprivation (2 days after surgery), 
the treated (3x + FD) and fellow control eyes (3x Fellow) are the same, indicating that 
surgery had no effect on refractive error.  For normal form-deprivation, the differences of 
refractive error between the form deprived (FD) and fellow eye (Fellow) are -4.04 ± 0.667 
D on the first measure (day 7), and -5.12 ± 0.659 D on the second measure (day 11).  
Nearly identical changes are seen in the treated animals with differences of -4.11 ± 0.675 D 
and -5.23 ± 0.612 D on the matching days.  Measurement of ocular length (from the front 
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Figure 5.12.  In vivo measurements of ocular parameters for form-deprived and normal 
fellow eyes: A) Measurements of refractive error were done by streak retinoscopy and 
spherical equivalent refractive error is presented as the mean of the measure from the 
horizontal and vertical meridians.  Two days after surgery there is no difference between 
the 3x EY treated or fellow eyes.  The 3x EY form-deprived (3x + FD) eyes exhibit similar 
responses as untreated form-deprived (FD) eyes in days 7 and 11.  The fellow eyes also 
show similar refractive states.  B) Ultrasound measurements of ocular length indicate no 
difference in the 3x EY treated and fellow eyes 2 days after surgery.  The ocular length at 
days 7 and 11 is similar in both the 3x EY treated animals and the untreated animals for 
both the FD and fellow eyes.  All the animals were approximately the same ages (~6 days 
old) at the beginning of form deprivation. 
A) B) Surgery 
FD
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of the cornea to the back of the sclera) by ultrasound also reveals similar behavior in 
the treated and untreated animals (Figure 5.12b).  On day 7, the myopic eye was 111 ± 20.4 
μm greater in length than the fellow eye.  By day 11, this length difference reduced some in 
the untreated animals, but remained the same in the 3x EY treated animals.  The similarities 
between the 3x EY treated (Set C) and the normal animals (Set B) indicates that this 
treatment does not have an effect on the eye.  We hypothesize that insufficient EY diffused 
into the tissue, motivating experiments with 10x EY (below). 
Although this treatment was not able to prevent myopia, the results were encouraging due 
to the lack of cytotoxic effects using 3x EY and irradiation, and the resilience of animals to 
the surgery.  Before examining higher doses in form-deprived animals, we began tests of 
higher doses in normal eyes to observe if they could tolerate the dose (Sets D & E).  At this 
time, analysis from Sets E and F is incomplete and only results from the other sets are 
presented. 
Eyes from Set D received the same irradiation protocol as those from Set C, but were given 
higher doses of drug (10x EY instead of 3x EY).  Measures of refractive error indicate that 
2 days after surgery there is a difference between the treated eye and untreated fellow eye 
of -3.11 ±  0.714 D (Figure 5.13a).  The treatment causes the eye to become more myopic.  
Over the course of the experiment, the treated eye becomes more hyperopic.  The fellow 
eye emmetropizes normally during this period.  The 10x EY treatment also causes an 
increased ocular length, and the difference between treated and untreated fellow eyes 
reduces over time (Figure 5.13b).  These initial differences were not seen in the 3x EY 
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treated eyes and they indicate that significant changes have occurred due to treatment 
with 10x EY. 
 
The change in ocular length is examined in greater detail using ultrasound biometry to 
evaluate all the ocular dimensions that contribute to ocular length (Figure 5.14).  The 
cornea and anterior chamber thickness (CAC) grows normally for both eyes (Figure 5.14a).  
The lens grows normally despite an initial difference at day 2 (Figure 5.14b).  The 
variability in day-to-day lens thickness suggests that the uncertainty in the measurement is 
greater than the error bars indicate.  The vitreous chamber elongates more slowly in the 
treated eye than in the untreated eye (Figure 5.14c).  There is no difference in retinal 
thickness (Figure 5.14d).  The choroid and sclera are both thicker in the treated eye (Figure 
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Figure 5.13.  Guinea pigs eyes undergoing normal growth were treated at day 0 with 10x 
EY and irradiation in the right eye and the fellow eye remained untreated.  Dotted lines are 
shown to guide the eye.  A)  Two days after the surgery, the refractive state of the treated 
eyes is significantly different from that of the untreated eye.  During normal growth, the 
fellow eye progresses toward emmetropia whereas the 10x EY treated eye maintains a 
stable refractive state, and becomes slightly more hyperopic over 17 days.  B) 
Measurements of ocular length are different at two days after surgery, with the treated eye 
being longer than the fellow eye.  Over 17 days, the rate of ocular length change is larger in 
the fellow eye than in the 10x EY treated eye.  Linear fits are used to illustrate the growth 
trends. 
A) B) 
Surgery
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5.14d).  The sum of these individual components gives the ocular length reported in 
Figure 5.13b: 
CAC + Lens + Vit + Ret + Scl + Chr = OL. 
1.06 mm + 3.53 mm + 3.02 mm + 0.16 mm + 0.11 mm + 0.11 mm = 7.99 mm. 
The slight differences in corneal power dissipate over the growth period (Figure 5.14e). 
The differences in the sclera, choroid, and vitreous chamber of the treated and fellow eyes 
persist over 15 days of observation.  Choroid thickness is known to increase with inhibitory 
growth signals, and the drug treatment may have triggered an inhibitory response.  The 
initial change in vitreous chamber depth may be explained by crosslinking of the sclera in 
an extended state.  The intraocular pressure increases during prolapsing, which could 
induce stretching of the sclera.  After prolapsing, the pressure decreases, and the sclera 
relaxes back to normal.  However, in a treated eye, the stretched state of the sclera might be 
crosslinked in place, causing noticeable shape differences.  Further tests such as MRI may 
be capable of examining the shape of the eye before and after prolapsing, with and without 
treatment. 
The data also suggests that the cornea grows in a normal manner in a treated eye despite the 
abnormal changes in vitreous chamber depth.  This is also seen with the normal growth of 
the lens.  The growth of the cornea and lens may not be coupled to axial length.  Using this 
method of crosslinking tissue, whether it is cornea or sclera, might enable researchers to 
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determine if there is a coupled feedback for growth of the ocular components in these 
animals. 
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Figure 5.14.  The ultrasound measurements are 
analyzed to measure corneal thickness and 
anterior chamber depth (CAC), lens thickness 
(Lens), vitreous chamber depth (Vit), retina 
thickness (Ret), choroid thickness (Chr), and 
sclera thickness (Scl) as F) illustrates.  There are 
no differences between the 10x EY treated and 
untreated fellow eyes for A) CAC, B) Lens, D) 
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5.4 Summary 
Were it possible to retard or prevent abnormal axial elongation of the globe in degenerative 
myopia, visual loss might be prevented.  Use of the expansion model in this study has 
allowed us to measure the progressive enlargement of the eye due to creep in the sclera.  
The ability of 1x EY and 10x EY to halt expansion in vitro in rabbit eyes indicates that the 
change in tissue properties upon treatment might prevent creep in vivo.  Results from the 
biocompatibility studies in rabbits and guinea pigs show only minor inflammation from the 
surgery, and no adverse responses due to treatment concentrations up to 10x EY.  Results 
from in vivo guinea pig studies demonstrate that the treatment with 3x EY did not alter 
ocular shape or prevent form-deprivation myopia.  However, the higher dose of 10x EY did 
substantially alter ocular parameters during normal growth, possibly due to elevated 
intraocular pressure during prolapsing at the time of irradiation.  The experiments establish 
protocols that may be extended to form-deprivation studies of 10x EY, perhaps with 
modification of the irradiation step to ensure that the globe is at normal intraocular 
pressure.  Future treatments of the entire eye, or specifically the posterior pole, are also 
recommended to test their ability to prevent form-deprivation myopia in the guinea pigs. 
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6.1 Introduction 
Keratoconus is a disorder that results in corneal thinning and is named for the conical shape 
that the cornea develops.1-3  The progressive distortion of corneal shape usually becomes 
noticeable in early adulthood, causing increasingly severe astigmatism, myopia, and 
higher-order aberrations that become difficult to correct by spectacles or contact lenses.  A 
number of different therapies have been tested in keratoconus as alternatives to contact 
lenses.  These include, thermokeratoplasty4, epikeratophakia5, and intracorneal ring 
segments (Intacs).6, 7  These treatments do not appear to stop progression of the disease; 
rather, they are alternatives to manage the refractive abnormalities induced by irregular 
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corneal thinning and ectasia, or expansion.  When distortions reach the point that 
refractive correction is no longer possible, corneal transplant is the only option. 
Recently, the pioneering work of Wollensak, Seiler, Spoerl, and co-workers demonstrated a 
potential treatment to arrest progression of keratoconus using photoactivated crosslinking.8-
21  Deriving from presumed weakened mechanical integrity of the cornea in keratoconus,22 
this novel crosslinking therapy is directed at increasing the cornea’s strength.  The 
procedure uses ultraviolet light (370 nm) to activate radical generation of riboflavin in the 
cornea.  The treatment consists of removing the corneal epithelium over a 7 mm diameter 
and then applying 0.1% riboflavin solution 5 minutes before, and then every 5 minutes 
thereafter, during a 30 minute UV-A irradiation.  Other than post-operative pain from 
corneal epithelial removal, the procedure is well tolerated.  In a series of 22 patients with 
progressive keratoconus, progression was stopped by treatment with UV-A and 
riboflavin.16  Mean follow up was nearly 2 years.  In 16 patients there was actual regression 
of the keratoconus with dioptric corneal flattening of 2 diopters.  After the epithelium 
regenerated, no adverse effects, e.g., on corneal transparency, were observed. 
Despite these encouraging results, there are several potential drawbacks to the current 
method.  First, removal of the epithelium is not desirable because the tight junctions of 
epithelial cells provide the first protective barrier for the cornea and prevent many 
molecules from penetrating this cell layer.  To avoid difficulties of delivering drug through 
the lipophilic epithelium and into the hydrophilic stroma, the epithelium is typically 
removed.  Although it re-grows, the epithelium is home to nearly 325,000 nerve endings23 
and its removal risks impaired sensation, leading to complications due to reduced blinking 
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reflex (failure to maintain proper corneal hydration and to sense foreign particles on 
the eye).  For this reason, the present study examines the ability of our chosen light-
activated drug, Eosin Y, to penetrate into the cornea with and without the epithelium 
present.  Second, UV light is potentially toxic, and when combined with riboflavin 
activation, has produced toxic effects on keratocytes, the cells responsible for ongoing 
repair and remodeling of the corneal stroma.  We study the ability to induce corneal 
crosslinking with a visible-light-activated system. Finally, the UV treatment lasts 35 
minutes, a relatively long time compared to refractive procedures that last only about two 
minutes.  Our demonstration of crosslinking uses a shorter treatment time totaling 10 
minutes (only 5 minutes of irradiation).  We compare treatment efficacy of the brief, 
visible-light protocol to the > 30 minute, UV-activated method using our intact globe 
expansion test. 
6.2 Materials and Methods 
6.2.1 Penetration of Molecules—Epithelial Barrier 
We have modified a slit lamp with filters and a digital camera to observe the depth profile 
of the fluorescence of drug molecules in enucleated porcine corneas (Figure 6.1).  A sheet 
of light, sent through a bandpass filter chosen to select light that efficiently excites Eosin Y 
(Filter 1 passes 500±20 nm), is incident on the cornea and both emitted and scattered light 
are viewed from an angle.  Scattered light, imaged without a filter between the specimen 
and the camera, is used to record the shape and position of the cornea.  The fluorescence of 
Eosin Y (EY), imaged through Filter 2 (which passes 560±25 nm) as shown in Figure 6.1a, 
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facilitates visualization of its penetration profile in the stroma (Figure 6.2b).  Untreated 
corneas show no fluorescence (field appears dark with Filter 2 in place).  In this manner, 
we are able to examine the amount of drug that crosses the epithelium and its distribution in 
the stroma. 
 
Enucleated eyes from 3–4 month old swine were obtained from Sierra for Medical Science.  
Fresh eyes were shipped in saline, on ice.  On arrival, the eyes were immediately (< 42 
hours post-mortem) cleaned by removing the tissue still attached to the eye.  Then the 
cornea was photographed in scattering mode, providing initial dimensions of the cornea, 
 
Figure 6.1.  A) Apparatus for imaging the cornea uses a slit lamp to 
provide a sheet of light and uses a band pass filter (500±20 nm) to reject 
light outside the absorption band of Eosin Y (EY).  Filter 2 (560±25 
nm) is only used to image the fluorescence of EY; it is removed when 
images of scattered light are acquired.  B) Photographs reveal a cross 
section of the cornea with the fluorescence profile inside the stroma. 
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and fluorescence mode, providing baseline measures of background fluorescence.  The 
epithelium was either removed with a scalpel or left intact before the eye was placed in 2 
ml of treatment solution (Table 1).  Eyes were left in solution for 1 hour and then removed, 
rinsed with approximately 4 ml of Dulbecco’s PBS and photographed in both scattering 
and fluorescence mode on the slit lamp.  After this treatment, eyes with intact epithelium 
were found to have very strong absorption and fluorescence associated with their 
epithelium.  To image fluorescence in their stroma, the epithelium was removed by 
scraping with a scalpel and they were photographed again.  Removal of the epithelium at 
this step allows excitation light to reach the stroma. 
Treatment Solutions EosinY (mM) Triethanolamine (mM) 
1x EY 0.0289 90 
35x EY 1 90 
350x EY 10 225 
Table 6.1. Treatment Solutions in Dulbecco’s Phosphate-Buffered 
Saline. 
 
 
Figure 6.2.  Slit lamp images of A) scattered light, revealing 
the full thickness of the treated cornea (without Filter 2), and 
B) filtered light, isolating the fluorescence emission of Eosin 
Y (with Filter 2, as shown in Figure 1A) 
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6.2.2 In Vitro Application and In Vitro Expansion 
We use the intact globe method, established in Chapters 2 and 5, to quantitatively compare 
treated and control eyes with respect to their resistance to corneal expansion. 
Tissue Preparation:  Eyes from 2–3 week old New Zealand White Rabbits (provided by 
collaborator Dr. Keith Duncan at the University of California at San Francisco) were stored 
in saline on ice for use within 48 hours of enucleation.  The epithelium was removed by 
scraping a scalpel blade across the cornea.  Removal was confirmed by visual inspection of 
the corneal surface.  The extraorbital tissues were removed to expose the sclera and ensure 
accurate analysis of the eye shape.  The eyes were then put into DPBS until treatment (at 
least 30 minutes and not more than 120 minutes). 
Materials:   
We tested three treatment solutions:  
“1x EY”: 0.0289 mM EY with 90 mM TEOA in DPBS,  
“10x EY”: 0.289 mM EY with 90 mM TEOA and 2% w/w hyaluronic acid (HA) in DPBS, 
and   
“R/UVA”: 2.09 mM (0.1% w/w) riboflavin-5′-phosphate sodium salt hydrate and 20% w/w 
T-500 Dextran in DPBS.   
Respective controls for each group used the treatment vehicle without EY or TEOA (i.e., 
DPBS, 2% HA in DPBS, and 20% T-500 Dextran in DPBS, respectively). 
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The addition of 2% HA and dextran are to increase viscosity so that the treatment 
could be applied topically and to maintain hydration of the cornea while doing so (Table 
6.2).   
 Treatment Formulation Vehicle Delivery Method 
1x EY Treated 0.0289 mM EY and 90 mM TEOA 
1x EY Control None DPBS Soaking 
10x EY Treated 0.289 mM EY and 90 mM TEOA 
10x EY Control None 
2% HA in 
DPBS Gel 
R/UVA Treated 2.09 mM riboflavin-5′-phosphate 
R/UVA Control  None 
20% Dextran 
in DPBS Viscous Drops 
Table 6.2.  Treatments and Respective Controls Used for Corneal Expansion Studies 
 
Procedure:  The intact globes for 1x EY treated and control (fellow eye from the same 
animal) were placed cornea down in a holder such that 750 μL of their respective solutions 
just covered the cornea.  The eyes were soaked in this manner for 5 minutes in the dark.  
The eyes were removed from solution and dabbed with a Kimwipe to remove excess 
solution from the corneal surface.  Then the treated and fellow control eyes were  placed 
cornea up in two identical holders, each equipped with a circle of green light-emitting 
diodes (seven 5-mm LEDs at 525 ± 16 nm, 6–8 mW/cm2 in the plane of the cornea).  An 
aluminum foil mask was place over each specimen to cover the sclera, while leaving the 
cornea exposed.  Then the irradiation was applied for 5 minutes. 
The 10x EY treated and control corneas had the gel treatment solution spread over the 
cornea.  After allowing 5 minutes of diffusion time, the solution was removed with a 
spatula and the corneal surface was rinsed with DPBS.  Each of the eyes was placed under 
a green light source consisting of seven 5-mm LEDs at 525 ± 16 nm and 6–8 mW/cm2.   
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Using the same protocol described above, the corneas of the treated and fellow control 
eyes were irradiated simultaneously for 5 minutes while the remainder of the eye was 
protected from light exposure using an aluminum foil mask. 
The R/UVA treated and control eyes received drops of solution on the cornea for 5 minutes 
prior to irradiation, and then received fresh drops every 5 minutes during the 30 minute 
irradiation with 3 mW/cm2 of 370±5 nm ultraviolet light for 30 minutes.  Both eyes were 
irradiated at the same time. 
After irradiation, all the eyes were placed in DPBS for 30 minutes.  Treated and fellow 
control eyes were mounted into an intact globe expansion apparatus with two sites to 
ensure that both experienced the same ambient pressure and temperature, and the same 
imposed intraocular pressure, as described in Chapter 2.  To restore the native shape of the 
globes, they received a “prestress” of 22 mmHg for one hour, based on observations that 
showed that shape recovery required up to 45 minutes for some specimens.  Images were 
recorded at 15 minute intervals during the prestress period.  Then the imposed intraocular 
pressure was increased to 85 mmHg, a first image was required within a few seconds of the 
inception of elevated pressure and subsequent images were acquired at 15 minute intervals 
for 24 hours. 
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6.3 Results 
6.3.1 Penetration of Molecules—Epithelial Barrier 
Fluorescence emission from the stroma of eyes treated with the epithelium present is much 
weaker than that observed in specimens that had the epithelium removed prior to treatment  
(Figure 6.3):  1x EY penetrates the stroma of eyes with removed epithelium within an hour, 
but in eyes with the epithelium intact, 1x EY cannot be detected after 6 hours of soaking.  
This observation accords with prior literature indicating that the epithelium inhibits 
penetration of compounds closely related to EY (e.g., fluorescein). Nevertheless, 
significant penetration of EY across the epithelium is evident in corneas treated with high 
concentration solutions (35x EY and 350x EY).  These results indicate that EY penetration 
through the epithelium is possible.  Clinically, it is significant that removal of the 
epithelium may not be necessary for treatment. 
Note that this method has very low sensitivity relative to, for example, laser scanning 
confocal fluorescence microscopy.  Due to low sensitivity, soaking for at least 1 hour was 
needed to achieve detectable levels of fluorescence for 1x EY even without the epithelium 
present (Figure 6.3, left, second row).  The next section of this chapter discusses treatments 
with 1x EY that successfully stabilize deepithelialized corneas using a 5 minute soaking 
time.  While slit lamp photography may be used to make qualitative judgments of epithelial 
penetration, it cannot be used to quantify changes with the sensitivity required for our 
treatments.  Future studies with the more sensitive approach of confocal microscopy could 
be used to reveal the diffusion rates through the epithelium and within the stroma. 
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6.3.2 In Vitro Application and In Vitro Expansion 
All quantitative comparisons of treated and control eyes were performed using 
deepithelialized specimens.  This decision was based on observations made on intact globes 
with the epithelium present. An illustration is presented in Figure 6.4 (a and b) where the 
epithelium was left intact: the cornea behaves similarly for treated and control globes, 
while the expansion of the sclera is lower for the treated globe than for the fellow control.  
In contrast, if the epithelium is removed (Figure 6.4c, d), sufficient drug enters the cornea 
during the 5 minute soak to prevent corneal expansion (Figure 6.4c).  The behavior evident 
for this pair of eyes is statistically significant:  results for a group of 6 treated eyes and their 
Figure 6.3.  Slit lamp images of the stroma of enucleated porcine eyes that were treated 
either with their epithelium left intact (top row) or after de-epithelialization (bottom row) 
by immersion for 1 hour (or *6 hours) in treatment solutions (formulation described in 
Table 1).  Increasing the EY concentration increases the fluorescence inside the stroma. 
1x EY 35x EY 350x EY 
 VI-11
6 fellow controls (Figure 6.5) show that both cornea and sclera of deepithelialized 
globes are stabilized by treatment (further information on this set of data is given in 
Chapter 5).   
 
Although they are not from the same animal, comparison of the control eyes (Figure 6.4b 
and d) shows that control eyes with epithelium removed expand similarly to control eyes 
with epithelium intact.  Removal of the epithelium, used in the remainder of this section, 
 
Figure 6.4.  Traces of the globe perimeter show the initial 
shape and final shape after 24 hours of high pressure (85 
mmHg) for representative specimens that were fully 
immersed for 5 minutes in either 1x EY (treated) or DPBS 
control followed by irradiation of the entire globe for 5 
minutes (see Chapter 5 for further details).  The epithelium 
was left in place for the upper pair of eyes (A treated and B 
control). The epithelium was removed prior to soaking the 
lower pair of eyes (C treated and D control).  Effective 
stabilization of the cornea is observed in C, but not in A. 
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allows drug to penetrate into the corneal stroma with no other discernible effect on 
the intact globe expansion behavior. 
 
In relation to keratoconus, we examine the changes in dimensions of the cornea (CP, CD, 
and CL, defined in Figure 6.5).  In the control specimens, each of the three dimensions 
expands significantly under the influence of elevated pressure (approximately 12% for CP, 
10% for CD and 18% for CL).  The three groups of controls do not differ significantly, 
indicating that the formulation vehicles do not play a direct role in mechanical stabilization.  
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Figure 6.5.  Rabbit eyes with removed epithelium are subjected to a high pressure (85 
mmHg) for up to 24 hours, showing the ability of treatment of the entire eye with 1x EY 
to prevent the expansion of the sclera (top row) and cornea (middle row).  The relevant 
ocular dimensions are illustrated in the inset figure, and n is the number of eyes in each 
group. 
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Soaking the cornea in 1x EY for 5 minutes and irradiating with visible light for 5 
minutes reduces expansion of the cornea as compared to DPBS controls (Figure 6.6).  In 
anticipation of topical application of a viscous solution or gel on the cornea to administer 
the drug, a  more concentrated solution (10x EY) was made with a “viscoelastic” surgical 
aid (2% HA) that creates a gel.  It was applied to form a coating on the cornea.  This 
treatment showed enhanced ability to prevent expansion (Figure 6.6), consistent with the 
increased EY concentration.  For comparison to the treatment that is currently in FDA 
clinical trials for the treatment of keratoconus, we include a protocol that uses the same 
parameter values described for that clinical procedure.   The treated eyes in the R/UVA 
group show similar resistance to expansion as the 10x EY treated group (Table 6.3). The 
treatment of the whole eye with GA (Figure 2.26) gives an extreme degree of crosslinking 
that is presented here for comparison (Figure 6.6). 
Importantly, the intact globe expansion method provides a way to compare treatments for 
efficacy.  Tests using a few animals (8–10) are able to distinguish treatments and to screen 
variations on the procedure to improve the treatment.  Further, the results of the R/UVA 
treatment provide a benchmark for identifying clinically relevant treatments. 
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1x EY 10x EY 2% HA Riboflavin GA Corneal 
Dimension Treated Control Treated Control Treated Control Treated 
# samples 5 5 4 4 5 5 6 
CP 4.5±3.14 12.6±3.80 1.9±0.96 14.8±4.09 1.7±2.22 12.2±3.53 -0.3±0.93
CD 5.0±2.70 9.3±2.63 2.2±0.69 10.8±2.96 2.0±2.47 10.6±3.80 0.2±0.88
CL 3.4±6.99 19.7±7.05 1.7±1.84 23.6±8.38 1.7±3.06 16.0±4.50 -0.9±1.11
Table 6.3. Keratoconus Treatments—Numerical Values of Data Presented in Figure 6.6 
 
6.4 Summary 
Successful treatment of keratoconus by crosslinking the constitutents of the cornea depends 
on penetration of the photoactivated formulation into the tissue and the activation of the 
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Measurement Description
 1x EY Control (5)
 10x EY Control (4)
 R/UVA Control (5)
 1x EY Treated (5)
 10x EY Treated (4)
 R/UVA Treated (5)
 GA Treated (6)
Figure 6.6.  In vitro treated cornea after 24 hour expansion—Corneas treated with 1x EY 
in DPBS and visible light, 10x EY in 2% HA and visible light, R/UVA in 20% dextran 
and ultraviolet light, and GA all show reduced expansion compared to their respective 
controls (DPBS, 2% HA, and 20% dextran).  Treatment effectiveness increases from left 
to right, with 1x EY least effective and GA most effective.  In the middle, 10x EY and 
R/UVA are nearly equivalent.  Numbers in parentheses indicate the number of eyes. 
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drug with safe doses of light to produce a therapeutically significant stabilization of 
the tissue.  The in vitro studies presented in this chapter address each of these 
requiremements.  It is shown that EY readily penetrates into the cornea if the epithelium is 
removed.  If the epithelium remains on the cornea, partitioning of Eosin Y into the cornea 
is greatly reduced.  Nevertheless, with sufficiently high driving force (high EY 
concentration), EY does penetrate into the cornea. Furthermore, it penetrates to an extent 
visible with a relatively insensitive imaging system—representing a large excess over the 
concentration required to achieve an effect similar to the riboflavin/UVA treatment.  
Therefore, it may be possible to deliver treatment to the cornea without removing the 
epithelium, and future studies on increasing concentrations could achieve the desired 
mechanical stability.  Without the epithelium present, the 10x EY treatment shows 
strengthening capabilities comparable to the R/UVA treatment.  Clinically, the R/UVA 
treatment involves removing the epithelium, applying topical drops of treatment solution 
for 5 minutes, and irradiating for 30 minutes with ~3 mW/cm2 370 nm ultraviolet light 
while applying drops every 5 minutes.  The 10x EY treatment we have developed involves 
removing the epithelium, applying a viscous drug solution for 5 minutes, cleaning off 
excess drug, and irradiating with ~6 mW/cm2 514 nm visible light for 5 minutes.  The 10x 
EY treatment is shorter and uses visible light instead of UV in order to achieve the same 
effective prevention of expansion.  If the treatment also proves to be non-toxic and the 
cornea maintains optical clarity in vivo, this would be a potential treatment option for 
keratoconus. 
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